

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 3
MARCH 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 3

March 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 3
March 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

BIONICHE PHARMA USA LLC
(BIONICHE PHARMA USA)

MYLAN INSTITUTIONAL LLC
(MYLAN LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck

KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445			
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)			
MULTISOURCE	12825 (83.6%)	12900 (83.5)			
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)			
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)			
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES					
APPROVED	17	9			
NUMBER OF APPLICANTS	835	844			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 33RD EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

1-1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIRROR PHARMS LLC 500MG;50MG;40MG

A040883 001 Dec 23, 2008 Feb DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ MIKART 356.4MG;30MG;16MG

A040109 001 Aug 26, 1997 Feb DISC

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

@ MIKART 712.8MG;60MG;32MG

A040316 001 Apr 28, 1999 Feb DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ MIKART 650MG;30MG

A089231 001 Mar 03, 1986 Feb DISC

@ 650MG;60MG

A089363 001 Sep 09, 1991 Feb DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MIKART 500MG;5MG

A081067 001 Nov 30, 1989 Feb DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MIKART 500MG;2.5MG

A089698 001 Aug 25, 1989 Feb DISC

@ 650MG;5MG

A040849 001 Jun 09, 2010 Feb DISC

>A> AA TRIS PHARMA INC 325MG;5MG

A202214 001 Mar 27, 2013 Mar NEWA

>A> AA 325MG;7.5MG

A202214 002 Mar 27, 2013 Mar NEWA

>A> AA 325MG;10MG

A202214 003 Mar 27, 2013 Mar NEWA

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

@ WATSON LABS 250MG

A088882 001 Oct 22, 1985 Jan DISC

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP SAGENT AGILA EQ 500MG BASE/VIAL

A200880 001 May 09, 2012 Jan CAHN

ACITRETIN

CAPSULE; ORAL

ACITRETIN

>A> AB BARR LABS INC 10MG

A091455 001 Apr 04, 2013 Mar NEWA

>A> AB 17.5MG

A202897 001 Apr 04, 2013 Mar NEWA

>A> AB 22.5MG

A202897 002 Apr 04, 2013 Mar NEWA

>A> AB 25MG

A091455 002 Apr 04, 2013 Mar NEWA

SORIATANE

>D> STIEFEL LABS INC 10MG

N019821 001 Oct 28, 1996 Mar CFTG

>A> AB 10MG

N019821 001 Oct 28, 1996 Mar CFTG

>D> 17.5MG

N019821 003 Aug 06, 2009 Mar CFTG

>A> AB 17.5MG

N019821 003 Aug 06, 2009 Mar CFTG

CAPSULE; ORAL

SORIATANE

>D>		STIEFEL LABS INC	22.5MG	N019821 004	Aug 06, 2009	Mar	CFTG
>A>	AB		22.5MG	N019821 004	Aug 06, 2009	Mar	CFTG
>D>		+	25MG	N019821 002	Oct 28, 1996	Mar	CFTG
>A>	AB	+	25MG	N019821 002	Oct 28, 1996	Mar	CFTG

ACYCLOVIR

OINTMENT; TOPICAL

>A>		ACYCLOVIR					
>A>	AB	MYLAN PHARMS INC	5%	A202459 001	Apr 03, 2013	Mar	NEWA
		ZOVIRAX					
>D>		+ VALEANT INTL	5%	N018604 001	Mar 29, 1982	Mar	CFTG
>A>	AB	+	5%	N018604 001	Mar 29, 1982	Mar	CFTG

ALBENDAZOLE

TABLET; ORAL

ALBENZA

	+	AMEDRA PHARMS	200MG	N020666 001	Jun 11, 1996	Feb	CAHN
--	---	---------------	-------	-------------	--------------	-----	------

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	+	MYLAN SPECLT	EQ 0.083% BASE	A072652 001	Feb 21, 1992	Jan	CAHN
>D>	AN	WOCKHARDT	EQ 0.083% BASE	A075394 001	Nov 22, 1999	Mar	DISC
>A>		@ WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394 001	Nov 22, 1999	Mar	DISC

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

AA		ROXANE	EQ 70MG BASE/75ML	A090520 001	Feb 25, 2013	Feb	NEWA
		FOSAMAX					
AA	+	MERCK	EQ 70MG BASE/75ML	N021575 001	Sep 17, 2003	Feb	CFTG

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

		TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271 001	Jan 25, 2013	Jan	NEWA
			EQ 12.5MG BASE	N022271 002	Jan 25, 2013	Jan	NEWA
	+		EQ 25MG BASE	N022271 003	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

		TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414 001	Jan 25, 2013	Jan	NEWA
	+		EQ 12.5MG BASE;1GM	N203414 002	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL

OSEN

		TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426 004	Jan 25, 2013	Jan	NEWA
			EQ 12.5MG BASE;EQ 30MG BASE	N022426 005	Jan 25, 2013	Jan	NEWA
			EQ 12.5MG BASE;EQ 45MG BASE	N022426 006	Jan 25, 2013	Jan	NEWA
			EQ 25MG BASE;EQ 15MG BASE	N022426 001	Jan 25, 2013	Jan	NEWA
			EQ 25MG BASE;EQ 30MG BASE	N022426 002	Jan 25, 2013	Jan	NEWA
	+		EQ 25MG BASE;EQ 45MG BASE	N022426 003	Jan 25, 2013	Jan	NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA

EQ 12.5MG BASE;EQ 15MG BASE

N022426 004 Jan 25, 2013 Feb CAIN

EQ 12.5MG BASE;EQ 30MG BASE

N022426 005 Jan 25, 2013 Feb CAIN

EQ 12.5MG BASE;EQ 45MG BASE

N022426 006 Jan 25, 2013 Feb CAIN

EQ 25MG BASE;EQ 15MG BASE

N022426 001 Jan 25, 2013 Feb CAIN

EQ 25MG BASE;EQ 30MG BASE

N022426 002 Jan 25, 2013 Feb CAIN

+

EQ 25MG BASE;EQ 45MG BASE

N022426 003 Jan 25, 2013 Feb CAIN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>D> AP

HOSPIRA

EQ 250MG BASE/ML

A063264 001 Nov 30, 1994 Mar DISC

>A>

@

EQ 250MG BASE/ML

A063264 001 Nov 30, 1994 Mar DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

>A> AMLODIPINE BESYLATE AND VALSARTAN

>A> AB

PAR PHARM INC

EQ 5MG BASE;160MG

A090011 001 Mar 28, 2013 Mar NEWA

>A> AB

EQ 5MG BASE;320MG

A090144 001 Mar 28, 2013 Mar NEWA

>A> AB

EQ 10MG BASE;160MG

A090011 002 Mar 28, 2013 Mar NEWA

>A> AB

EQ 10MG BASE;320MG

A090011 004 Mar 28, 2013 Mar NEWA

EXFORGE

>D>

NOVARTIS

EQ 5MG BASE;160MG

N021990 002 Jun 20, 2007 Mar CFTG

>A> AB

EQ 5MG BASE;160MG

N021990 002 Jun 20, 2007 Mar CFTG

>D>

EQ 5MG BASE;320MG

N021990 004 Jun 20, 2007 Mar CFTG

>A> AB

EQ 5MG BASE;320MG

N021990 004 Jun 20, 2007 Mar CFTG

>D>

+

EQ 10MG BASE;160MG

N021990 003 Jun 20, 2007 Mar CFTG

>A> AB

+

EQ 10MG BASE;160MG

N021990 003 Jun 20, 2007 Mar CFTG

>D>

+

EQ 10MG BASE;320MG

N021990 005 Jun 20, 2007 Mar CFTG

>A> AB

+

EQ 10MG BASE;320MG

N021990 005 Jun 20, 2007 Mar CFTG

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP

CARDINAL HEALTH 414

30MCI-300MCI/8ML (3.75-37.5MCI/ML)

A203700 001 Feb 25, 2013 Feb NEWA

AP

+

FEINSTEIN

30MCI-300MCI/8ML (3.75-37.5MCI/ML)

N022119 001 Aug 23, 2007 Feb CFTG

AP

MCPRF

30MCI-300MCI/8ML (3.75-37.5MCI/ML)

A203321 001 Feb 25, 2013 Feb NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ RANBAXY

200MG/5ML

A065113 001 Nov 29, 2002 Feb DISC

@

400MG/5ML

A065113 002 Nov 29, 2002 Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

>D> AB

DAVA PHARMS INC

125MG

A064139 001 Jan 29, 1996 Mar DISC

>A>

@

125MG

A064139 001 Jan 29, 1996 Mar DISC

>D> AB

250MG

A064139 002 Jan 29, 1996 Mar DISC

>A>

@

250MG

A064139 002 Jan 29, 1996 Mar DISC

@ RANBAXY

200MG

A065060 001 Nov 29, 2000 Feb DISC

@

400MG

A065060 002 Nov 29, 2000 Feb DISC

TABLET, CHEWABLE; ORAL

AMOXIL

@ DR REDDYS LABS INC	200MG	N050761 001	Apr 15, 1999	Feb	DISC
@	400MG	N050761 002	Apr 15, 1999	Feb	DISC

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

@ AUROBINDO PHARMA LTD	200MG	A065324 001	Jan 17, 2007	Jan	DISC
@	400MG	A065324 002	Jan 17, 2007	Jan	DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536 001	Feb 12, 2013	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076536 002	Feb 12, 2013	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076536 003	Feb 12, 2013	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A076536 004	Feb 12, 2013	Jan	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076536 005	Feb 12, 2013	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076536 006	Feb 12, 2013	Jan	NEWA

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@ TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472 001	Sep 30, 2003	Jan	DISC
@	2.5MG;2.5MG;2.5MG;2.5MG	A040472 002	Sep 30, 2003	Jan	DISC
@	5MG;5MG;5MG;5MG	A040472 003	Sep 30, 2003	Jan	DISC
@	7.5MG;7.5MG;7.5MG;7.5MG	A040472 004	Sep 30, 2003	Jan	DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>A>	AP	ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884 001	Apr 03, 2013	Mar	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A090884 002	Apr 03, 2013	Mar	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A090884 003	Apr 03, 2013	Mar	NEWA
>A>	AP		EQ 10GM BASE/VIAL	A090889 001	Apr 03, 2013	Mar	NEWA

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

@ KUDCO IRELAND	1MG	A091331 001	Jan 05, 2011	Feb	DISC
-----------------	-----	-------------	--------------	-----	------

ARIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

OTSUKA PHARM CO LTD	300MG/VIAL	N202971 001	Feb 28, 2013	Feb	NEWA
+	400MG/VIAL	N202971 002	Feb 28, 2013	Feb	NEWA

ATENOLOL

TABLET; ORAL

ATENOLOL

>D>	AB	WATSON LABS	50MG	A073352 001	Dec 27, 1991	Mar	DISC
>A>		@	50MG	A073352 001	Dec 27, 1991	Mar	DISC
>D>	AB		100MG	A073353 001	Dec 27, 1991	Mar	DISC
>A>		@	100MG	A073353 001	Dec 27, 1991	Mar	DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

>A>	AB	KUDCO IRELAND	EQ 10MG BASE	A091624 001	Apr 05, 2013	Mar	NEWA
>A>	AB		EQ 20MG BASE	A091624 002	Apr 05, 2013	Mar	NEWA
>A>	AB		EQ 40MG BASE	A091624 003	Apr 05, 2013	Mar	NEWA
>A>	AB		EQ 80MG BASE	A091624 004	Apr 05, 2013	Mar	NEWA

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

>A>	AP	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923 001	Apr 02, 2013	Mar	NEWA
-----	----	--------------------	--------------------	-------------	--------------	-----	------

BACITRACIN

>D> POWDER; FOR RX COMPOUNDING

>D> BACI-RX

>D>		X GEN PHARMS	5,000,000 UNITS/BOT	A061580 001		Mar	DISC
-----	--	--------------	---------------------	-------------	--	-----	------

>A>		@	5,000,000 UNITS/BOT	A061580 001		Mar	DISC
-----	--	---	---------------------	-------------	--	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

	@	COREPHARMA	50MG	A040714 001	Oct 29, 2007	Feb	DISC
--	---	------------	------	-------------	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

	AP	NAVINTA LLC	1MG/ML	A091525 001	Feb 05, 2013	Jan	NEWA
--	----	-------------	--------	-------------	--------------	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

>D>	AA	PROSAM LABS	0.5MG	A040699 001	Feb 14, 2008	Mar	DISC
-----	----	-------------	-------	-------------	--------------	-----	------

>A>		@	0.5MG	A040699 001	Feb 14, 2008	Mar	DISC
-----	--	---	-------	-------------	--------------	-----	------

>D>	AA		1MG	A040705 001	Feb 14, 2008	Mar	DISC
-----	----	--	-----	-------------	--------------	-----	------

>A>		@	1MG	A040705 001	Feb 14, 2008	Mar	DISC
-----	--	---	-----	-------------	--------------	-----	------

>D>	AA		2MG	A040706 001	Feb 14, 2008	Mar	DISC
-----	----	--	-----	-------------	--------------	-----	------

>A>		@	2MG	A040706 001	Feb 14, 2008	Mar	DISC
-----	--	---	-----	-------------	--------------	-----	------

BEXAROTENE

GEL; TOPICAL

TARGRETIN

+		VALEANT PHARMS INC	1%	N021056 001	Jun 28, 2000	Feb	CAHN
---	--	--------------------	----	-------------	--------------	-----	------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

	@	PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201 001	Dec 13, 2007	Feb	DISC
--	---	-----------------	-----------------------	-------------	--------------	-----	------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

AT		LUITPOLD	0.09%	A202030 001	Jan 09, 2013	Feb	CAHN
----	--	----------	-------	-------------	--------------	-----	------

BUDESONIDE

TABLET, EXTENDED RELEASE; ORAL
UCERIS

+ SANTARUS 9MG N203634 001 Jan 14, 2013 Jan NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE;EQ 0.5MG BASE	A091422 001	Feb 22, 2013	Feb	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A091422 002	Feb 22, 2013	Feb	NEWA
AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136 001	Feb 22, 2013	Feb	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A203136 002	Feb 22, 2013	Feb	NEWA
>D>	SUBOXONE					
>D>	AB RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Mar	DISC
>A>	@	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Mar	DISC
	AB	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Feb	CFTG
>D>	AB +	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Mar	DISC
>A>	@	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Mar	DISC
	AB +	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Feb	CFTG

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

@ TEVA	75MG	A075310 001	Nov 29, 1999	Feb	CDFR
@	100MG	A075310 002	Nov 29, 1999	Feb	DISC

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

>D>	AB	PERRIGO ISRAEL	2%	A200923 001	May 18, 2012	Mar	CRLD
>A>	+		2%	A200923 001	May 18, 2012	Mar	CRLD
>D>		GYNAZOLE-1					
>D>	AB +	KV PHARM	2%	N019881 001	Feb 07, 1997	Mar	DISC
>A>	@		2%	N019881 001	Feb 07, 1997	Mar	DISC

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	APOTEX CORP	0.5MG	A201503 001	Mar 08, 2013	Feb	NEWA
----	-------------	-------	-------------	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

>D>	@ MIKART	100MG;1MG	A040590 001	Sep 16, 2005	Mar	CMFD
>A>	AA	100MG;1MG	A040590 001	Sep 16, 2005	Mar	CMFD
	@	100MG;1MG	A040590 001	Sep 16, 2005	Jan	DISC

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A203135 001	Feb 07, 2013	Jan	NEWA
----	----------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB	INVAGEN PHARMS	EQ 169MG CALCIUM	A202420 001	Feb 05, 2013	Jan	NEWA
----	----------------	------------------	-------------	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

>D>	ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER								
>D>	+ B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;7 4MG/100ML;640MG/100ML;500MG/100ML ;74MG/100ML	N019867 001	Dec 20,	1993	Mar	DISC		
>A>	@	35MG/100ML;5GM/100ML;30MG/100ML;7 4MG/100ML;640MG/100ML;500MG/100ML ;74MG/100ML	N019867 001	Dec 20,	1993	Mar	DISC		

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS 18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N020374 001 Jun 13, 1994 Feb DISC

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS 18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N020374 002 Jun 13, 1994 Feb DISC

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS 18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N020374 003 Jun 13, 1994 Feb DISC

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS 18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N020374 004 Jun 13, 1994 Feb DISC

>A> CANAGLIFLOZIN

>A> TABLET; ORAL

>A> INVOKANA

>A> JANSSEN RES AND DEV 100MG N204042 001 Mar 29, 2013 Mar NEWA

>A> + 300MG N204042 002 Mar 29, 2013 Mar NEWA

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB ACCORD HLTHCARE 25MG;100MG A202323 001 Feb 08, 2013 Jan NEWA

AB 50MG;200MG A202323 002 Feb 08, 2013 Jan NEWA

CARBINOXAMINE MALEATE

>A> SUSPENSION, EXTENDED RELEASE; ORAL

>A> KARBINAL ER

>A> + TRIS PHARMA INC 4MG/5ML N022556 001 Mar 28, 2013 Mar NEWA

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

@ PLIVA 50MG/VIAL A076602 001 Nov 16, 2004 Feb DISC

@ 150MG/VIAL A076602 002 Nov 16, 2004 Feb DISC

@ 450MG/VIAL A076602 003 Nov 16, 2004 Feb DISC

INJECTABLE; IV (INFUSION)

CARBOPLATIN

>D> AP FRESENIUS KABI USA 50MG/5ML (10MG/ML) A077266 001 Feb 15, 2006 Mar DISC

>A> @ 50MG/5ML (10MG/ML) A077266 001 Feb 15, 2006 Mar DISC

>D> AP 150MG/15ML (10MG/ML) A077266 002 Feb 15, 2006 Mar DISC

>A> @ 150MG/15ML (10MG/ML) A077266 002 Feb 15, 2006 Mar DISC

PARAPLATIN

>D> @ BRISTOL MYERS SQUIBB 50MG/5ML (10MG/ML) N020452 001 Jul 14, 2003 Mar CAHN

>D> @ 150MG/15ML (10MG/ML) N020452 002 Jul 14, 2003 Mar CAHN

INJECTABLE; IV (INFUSION)

PARAPLATIN

>D>	@	BRISTOL MYERS SQUIBB	450MG/45ML (10MG/ML)	N020452 003	Jul 14, 2003	Mar	CAHN
>D>	@		600MG/60ML (10MG/ML)	N020452 004	Jan 15, 2004	Mar	CAHN
>A>	@	CORDENPHARMA	50MG/5ML (10MG/ML)	N020452 001	Jul 14, 2003	Mar	CAHN
>A>	@		150MG/15ML (10MG/ML)	N020452 002	Jul 14, 2003	Mar	CAHN
>A>	@		450MG/45ML (10MG/ML)	N020452 003	Jul 14, 2003	Mar	CAHN
>A>	@		600MG/60ML (10MG/ML)	N020452 004	Jan 15, 2004	Mar	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

@	COREPHARMA	350MG	A040397 001	Sep 21, 2000	Feb	DISC
---	------------	-------	-------------	--------------	-----	------

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

>D>	+	ARBOR PHARMS INC	7.7MG	N020637 001	Sep 23, 1996	Mar	CAHN
>A>	+	ARBOR PHARMS LLC	7.7MG	N020637 001	Sep 23, 1996	Mar	CAHN

INJECTABLE; INJECTION

BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422 001		Jan	CAHN
---	-------------------	------------	-------------	--	-----	------

CARVEDILOL

TABLET; ORAL

CARVEDILOL

@	WOCKHARDT LTD	3.125MG	A078786 001	Dec 22, 2009	Feb	DISC
@		6.25MG	A078786 002	Dec 22, 2009	Feb	DISC
@		12.5MG	A078786 003	Dec 22, 2009	Feb	DISC
@		25MG	A078786 004	Dec 22, 2009	Feb	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

>D>	AB	TEVA PHARMS	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006	Mar	DISC
>D>	AB		EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006	Mar	DISC
>A>	@	TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006	Mar	DISC
>A>	@		EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006	Mar	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	+	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Feb	CRLD
AP	+		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Feb	CRLD
AP	+		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Feb	CRLD
AP	+		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Feb	CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

>D>	AP	SANDOZ	EQ 500MG BASE/VIAL	A090291 001	Dec 21, 2010	Mar	DISC
>A>	@		EQ 500MG BASE/VIAL	A090291 001	Dec 21, 2010	Mar	DISC
>D>	AP		EQ 1GM BASE/VIAL	A090291 002	Dec 21, 2010	Mar	DISC
>A>	@		EQ 1GM BASE/VIAL	A090291 002	Dec 21, 2010	Mar	DISC
>D>	AP		EQ 2GM BASE/VIAL	A090291 003	Dec 21, 2010	Mar	DISC
>A>	@		EQ 2GM BASE/VIAL	A090291 003	Dec 21, 2010	Mar	DISC

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

+	LUPIN LTD	500MG/5ML	N202091 001	Feb 20, 2013	Feb	CDFR
	LUPIN PHARMS	100MG/5ML	A065129 001	Feb 23, 2004	Feb	CDFR
		200MG/5ML	A065355 001	Apr 10, 2007	Feb	CDFR

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

>A>		ALKEM LABS LTD	EQ 333MG BASE	A090836 003	Mar 29, 2013	Mar	NEWA
>A>	AB		EQ 750MG BASE	A090836 004	Mar 29, 2013	Mar	NEWA
		KEFLEX					
>D>	+	SHIONOGI INC	EQ 750MG BASE	N050405 005	May 12, 2006	Mar	CTEC
>A>	AB	+	EQ 750MG BASE	N050405 005	May 12, 2006	Mar	CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	5MG/5ML	A090751 001	Dec 16, 2009	Feb	DISC
---	----------------------	---------	-------------	--------------	-----	------

CHLOROTHIAZIDE

TABLET; ORAL

DIURIL

@	OAK PHARMS AKORN	250MG	N011145 004		Jan	CAHN
@		500MG	N011145 002		Jan	CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

DIURIL

AP	+	OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145 005		Jan	CAHN
----	---	------------------	--------------------	-------------	--	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

+	CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307 001	Feb 20, 2013	Feb	NEWA
---	---------------	-----------------	-------------	--------------	-----	------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@	WATSON LABS INC	100MG	A088852 001	Sep 26, 1984	Jan	DISC
@		250MG	A088826 001	Sep 26, 1984	Jan	DISC

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

>A>		MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913 001	Mar 25, 2013	Mar	NEWA
>A>	AB		EQ 135MG FENOFIBRIC ACID	A200913 002	Mar 25, 2013	Mar	NEWA
		TRILIPIX					
>D>		ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224 001	Dec 15, 2008	Mar	CFTG
>A>	AB		EQ 45MG FENOFIBRIC ACID	N022224 001	Dec 15, 2008	Mar	CFTG
>D>	+		EQ 135MG FENOFIBRIC ACID	N022224 002	Dec 15, 2008	Mar	CFTG
>A>	AB	+	EQ 135MG FENOFIBRIC ACID	N022224 002	Dec 15, 2008	Mar	CFTG

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

@ TEVA PHARMS

8%

A078079 001 Sep 18, 2007 Jan DISC

PENLAC

AT + VALEANT INTL

8%

N021022 001 Dec 17, 1999 Feb CAHN

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

@ HQ SPCLT PHARMA

10MG/VIAL

N018057 001

Jan CAHN

@

50MG/VIAL

N018057 002

Jan CAHN

PLATINOL-AQ

@ HQ SPCLT PHARMA

0.5MG/ML

N018057 003 Jul 18, 1984 Jan CAHN

@

1MG/ML

N018057 004 Nov 08, 1988 Jan CAHN

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ COREPHARMA

EQ 10MG BASE

A077036 001 Oct 28, 2004 Feb DISC

@

EQ 20MG BASE

A077036 002 Oct 28, 2004 Feb DISC

@

EQ 40MG BASE

A077036 003 Oct 28, 2004 Feb DISC

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

>D> AA

SILARX

EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997 Mar DISC

>A>

@

EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997 Mar DISC

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+ MEDICINES CO

25MG/50ML (0.5MG/ML)

N022156 001 Aug 01, 2008 Feb CAIN

+

50MG/100ML (0.5MG/ML)

N022156 002 Aug 01, 2008 Feb CAIN

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

>A> AP

AKORN INC

EQ 6MG BASE/ML

A203048 001 Apr 04, 2013 Mar NEWA

>A> AP

EQ 12MG BASE/ML

A203048 002 Apr 04, 2013 Mar NEWA

>A> AP

EQ 18MG BASE/ML

A203048 003 Apr 04, 2013 Mar NEWA

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ PERRIGO NEW YORK

EQ 1% BASE

A064050 001 Nov 30, 1995 Feb DISC

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

@ APOTEX INC

0.5MG

A075468 001 Oct 06, 2000 Feb DISC

@

1MG

A075468 002 Oct 06, 2000 Feb DISC

@

2MG

A075468 003 Oct 06, 2000 Feb DISC

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

>A>	AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925 001	Mar 27, 2013	Mar	NEWA
>A>	AB		EQ 300MG BASE	A202925 002	Mar 27, 2013	Mar	NEWA

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

>D>	+	DOUGLAS PHARMS	50MG/ML	N203479 001	Feb 06, 2013	Mar	CAHN
	+		50MG/ML	N203479 001	Feb 06, 2013	Feb	NEWA
>A>	+	JAZZ PHARMS III	50MG/ML	N203479 001	Feb 06, 2013	Mar	CAHN

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	MYLAN LLC	0.25MG/VIAL	A090574 001	Dec 17, 2009	Feb	CAHN
----	-----------	-------------	-------------	--------------	-----	------

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

>A>	AA	MICRO LABS LTD INDIA	100MG/5ML	A202745 001	Apr 04, 2013	Mar	NEWA
-----	----	----------------------	-----------	-------------	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	IVAX INTL	15MG	N021777 001	Feb 01, 2007	Jan	CAHN
AB	+	30MG	N021777 002	Feb 01, 2007	Jan	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

AB	TWI PHARMS INC	15MG	A091281 001	Jan 31, 2013	Jan	NEWA
AB		30MG	A091281 002	Jan 31, 2013	Jan	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>A>	AB	MYLAN PHARMS INC	7.5MG	A073144 003	Mar 25, 2013	Mar	NEWA
>D>	AB	PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Mar	DISC
>A>	@	5MG	A077291 001	Feb 03, 2006	Mar	DISC	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

>D>	AT	AKORN	2%	A040165 001	Jan 13, 1997	Mar	DISC
>A>	@	2%	A040165 001	Jan 13, 1997	Mar	DISC	

CYCLOGYL

>D>	AT	+	ALCON	2%	A084108 001	Mar	CTEC
>A>		+	ALCON LABS INC	2%	A084108 001	Mar	CTEC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

>D>	AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003	Mar	CTNA
>D>	AP	+		1GM/VIAL	N012142 004	Aug 30, 1982	Mar
>D>	AP	+		2GM/VIAL	N012142 005	Aug 30, 1982	Mar
>A>			CYTOXAN (LYOPHILIZED)				
>A>	AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003	Mar	CTNA
		@	500MG/VIAL	N012142 008	Jan 04, 1984	Jan	CTNA

		INJECTABLE; INJECTION				
>A>		CYTOXAN (LYOPHILIZED)				
>A>	AP	+	BAXTER HLTHCARE	1GM/VIAL	N012142 004	Aug 30, 1982 Mar CTNA
			@	1GM/VIAL	N012142 010	Sep 24, 1985 Jan CTNA
>A>	AP	+		2GM/VIAL	N012142 005	Aug 30, 1982 Mar CTNA
			@	2GM/VIAL	N012142 009	Dec 10, 1985 Jan CTNA
<u>CYPROHEPTADINE HYDROCHLORIDE</u>						
		SYRUP; ORAL				
		CYPROHEPTADINE HYDROCHLORIDE				
>A>	AA		PHARM ASSOC	2MG/5ML	A091295 001	Mar 28, 2013 Mar NEWA
<u>DESMOPRESSIN ACETATE</u>						
		INJECTABLE; INJECTION				
		DESMOPRESSIN ACETATE				
	AP		SUN PHARM INDS LTD	0.004MG/ML	A091280 001	Jan 25, 2013 Jan NEWA
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>						
		TABLET; ORAL-28				
		ENSKYCE				
	AB		LUPIN LTD	0.15MG;0.03MG	A201887 001	Mar 07, 2013 Feb NEWA
<u>DESVENLAFAXINE</u>						
>A>			TABLET, EXTENDED RELEASE; ORAL			
>A>			DESVENLAFAXINE			
>A>			ALEMBIC PHARMS LTD	50MG	N204150 001	Mar 04, 2013 Mar NEWA
>A>		+		100MG	N204150 002	Mar 04, 2013 Mar NEWA
<u>DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
		SUSPENSION/DROPS; OPHTHALMIC				
		NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE				
			@ ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986 Jan DISC
<u>DEXMEDETOMIDINE HYDROCHLORIDE</u>						
		INJECTABLE; INJECTION				
		PRECEDEX				
>A>		+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038 002	Mar 13, 2013 Mar NEWA
>A>		+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038 003	Mar 13, 2013 Mar NEWA
<u>DEXTROSE; POTASSIUM CHLORIDE</u>						
		INJECTABLE; INJECTION				
		POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER				
			@ B BRAUN	5GM/100ML;220MG/100ML	N018744 003	Nov 09, 1982 Jan DISC
<u>DILTIAZEM HYDROCHLORIDE</u>						
		CAPSULE, EXTENDED RELEASE; ORAL				
		DILTIAZEM HYDROCHLORIDE				
AB3			PAR PHARM	120MG	A074984 001	Dec 20, 1999 Jan CAHN
AB3				180MG	A074984 002	Dec 20, 1999 Jan CAHN
AB3				240MG	A074984 003	Dec 20, 1999 Jan CAHN
AB3				300MG	A074984 004	Dec 20, 1999 Jan CAHN
AB4			SANDOZ	120MG	A091022 001	Sep 28, 2012 Feb CAHN
AB4				180MG	A091022 002	Sep 28, 2012 Feb CAHN
AB4				240MG	A091022 003	Sep 28, 2012 Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB4	SANDOZ	300MG	A091022 004	Sep 28, 2012	Feb	CAHN
AB4		360MG	A091022 005	Sep 28, 2012	Feb	CAHN
AB4		420MG	A091022 006	Sep 28, 2012	Feb	CAHN

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@ DAVA PHARMS INC

30MG

A074093 001 Nov 05, 1992 Jan DISC

@

60MG

A074093 002 Nov 05, 1992 Jan DISC

@

90MG

A074093 003 Nov 05, 1992 Jan DISC

@

120MG

A074093 004 Nov 05, 1992 Jan DISC

>A> DIMETHYL FUMARATE

>A> CAPSULE, DELAYED RELEASE; ORAL

>A> TECFIDERA

>A> BIOGEN IDEC INC 120MG

N204063 001 Mar 27, 2013 Mar NEWA

>A> + 240MG

N204063 002 Mar 27, 2013 Mar NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

>D> + WATSON LABS 10MG/ML

A080873 001 Mar DISC

>D> AP 50MG/ML

A080873 002 Mar DISC

>A> @ WATSON LABS INC 10MG/ML

A080873 001 Mar DISC

>A> @ 50MG/ML

A080873 002 Mar DISC

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

>A> AP BD RX 50MG/ML

A091526 001 Mar 26, 2013 Mar NEWA

>D> AP WATSON LABS 50MG/ML

A080873 003 Mar DISC

>A> @ WATSON LABS INC 50MG/ML

A080873 003 Mar DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

>D> AB TEVA PHARMS EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009 Mar DISC

>A> @ TEVA PHARMS USA EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009 Mar DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

@ ACCORD HLTHCARE

5MG

A201335 001 Aug 29, 2011 Jan DISC

@

10MG

A201335 002 Aug 29, 2011 Jan DISC

AB ALEMBIC PHARMS LTD 5MG

A201724 001 Feb 25, 2013 Feb NEWA

AB 10MG

A201724 002 Feb 25, 2013 Feb NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ WATSON LABS INC

EQ 1MG BASE

A075426 001 Oct 18, 2000 Jan DISC

@

EQ 2MG BASE

A075426 002 Oct 18, 2000 Jan DISC

@

EQ 4MG BASE

A075426 003 Oct 18, 2000 Jan DISC

@

EQ 8MG BASE

A075426 004 Oct 18, 2000 Jan DISC

DOXEPIIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPIIN HYDROCHLORIDE

>D> AA PHARM ASSOC EQ 10MG BASE/ML

A075924 001 Jan 15, 2004 Mar DISC

		CONCENTRATE; ORAL									
		DOXEPIN HYDROCHLORIDE									
>A>		@ PHARM ASSOC	EQ 10MG BASE/ML			A075924	001	Jan 15, 2004	Mar	DISC	
<u>DOXORUBICIN HYDROCHLORIDE</u>											
		INJECTABLE; INJECTION									
		DOXORUBICIN HYDROCHLORIDE									
>A>	AP	SAGENT PHARMS	2MG/ML			A091495	001	Mar 18, 2013	Mar	NEWA	
		INJECTABLE, LIPOSOMAL; INJECTION									
		DOXIL									
	AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)		N050718	001	Nov 17, 1995	Jan	CFTG	
	AB	+		50MG/25ML (2MG/ML)		N050718	002	Jun 13, 2000	Jan	CFTG	
		DOXORUBICIN HYDROCHLORIDE									
	AB		SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)		A203263	001	Feb 04, 2013	Jan	NEWA	
	AB			50MG/25ML (2MG/ML)		A203263	002	Feb 04, 2013	Jan	NEWA	
<u>DOXYCYCLINE</u>											
		FOR SUSPENSION; ORAL									
		DOXYCYCLINE									
>A>	AB		LUPIN LTD	EQ 25MG BASE/5ML		A201678	001	Mar 18, 2013	Mar	NEWA	
<u>DOXYCYCLINE HYCLATE</u>											
		TABLET; ORAL									
		DOXYCYCLINE HYCLATE									
>A>		@ BLU CARIBE INC	EQ 50MG BASE			A062269	003		Mar	CAHN	
>A>		@	EQ 100MG BASE			A062269	002	Nov 08, 1982	Mar	CAHN	
>D>		@ TRUXTON INC	EQ 50MG BASE			A062269	003		Mar	CAHN	
>D>		@	EQ 100MG BASE			A062269	002	Nov 08, 1982	Mar	CAHN	
<u>ECONAZOLE NITRATE</u>											
		CREAM; TOPICAL									
		ECONAZOLE NITRATE									
>A>	AB		IGI LABS INC	1%		A076574	001	Dec 17, 2004	Mar	CAHN	
>D>	AB		PRASCO	1%		A076574	001	Dec 17, 2004	Mar	CAHN	
<u>EPIRUBICIN HYDROCHLORIDE</u>											
		INJECTABLE; INJECTION									
		EPIRUBICIN HYDROCHLORIDE									
		@ MYLAN LLC	50MG/25ML (2MG/ML)			A065371	001	Nov 28, 2007	Feb	DISC	
		@	200MG/100ML (2MG/ML)			A065371	002	Nov 28, 2007	Feb	DISC	
<u>ERYTHROMYCIN</u>											
		CAPSULE, DELAYED REL PELLETS; ORAL									
		ERYC									
>D>	AB	+	HOSPIRA	250MG		N050536	001		Mar	CAHN	
>A>	AB	+	MAYNE PHARMA	250MG		N050536	001		Mar	CAHN	
<u>ESOMEPRAZOLE SODIUM</u>											
		INJECTABLE; INTRAVENOUS									
		ESOMEPRAZOLE SODIUM									
>A>	AP		SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL		A200882	001	Mar 18, 2013	Mar	NEWA	
>A>	AP			EQ 40MG BASE/VIAL		A200882	002	Mar 18, 2013	Mar	NEWA	
		NEXIUM IV									
>D>		+	ASTRAZENECA	EQ 20MG BASE/VIAL		N021689	001	Mar 31, 2005	Mar	CFTG	
>A>	AP	+		EQ 20MG BASE/VIAL		N021689	001	Mar 31, 2005	Mar	CFTG	
>D>		+		EQ 40MG BASE/VIAL		N021689	002	Mar 31, 2005	Mar	CFTG	

INJECTABLE; INTRAVENOUS

NEXIUM IV

>A>	AP	+	ASTRAZENECA	EQ 40MG BASE/VIAL	N021689 002	Mar 31, 2005	Mar	CFTG
-----	----	---	-------------	-------------------	-------------	--------------	-----	------

ESZOPICLONE

TABLET; ORAL

>A> ESZOPICLONE

>A>	AB		MYLAN PHARMS INC	1MG	A091151 001	Mar 26, 2013	Mar	NEWA
>A>	AB			2MG	A091151 002	Mar 26, 2013	Mar	NEWA
>A>	AB			3MG	A091151 003	Mar 26, 2013	Mar	NEWA
>A>	AB		SUN PHARMA GLOBAL	1MG	A091103 001	Apr 03, 2013	Mar	NEWA
>A>	AB			2MG	A091103 002	Apr 03, 2013	Mar	NEWA
>A>	AB			3MG	A091103 003	Apr 03, 2013	Mar	NEWA

LUNESTA

>D>			SUNOVION PHARMS INC	1MG	N021476 001	Dec 15, 2004	Mar	CTEC
>A>	AB			1MG	N021476 001	Dec 15, 2004	Mar	CTEC
>D>				2MG	N021476 002	Dec 15, 2004	Mar	CTEC
>A>	AB			2MG	N021476 002	Dec 15, 2004	Mar	CTEC
>D>		+		3MG	N021476 003	Dec 15, 2004	Mar	CTEC
>A>	AB	+		3MG	N021476 003	Dec 15, 2004	Mar	CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

>A> DAYSEE

>A>	AB		LUPIN LTD	0.03MG;0.01MG;0.15MG,N/A	A091467 001	Apr 10, 2013	Mar	NEWA
>A>			QUARTETTE					
>A>		+	TEVA BRANDED PHARM	0.02MG;0.15MG;0.025MG;0.15MG;0.03MG;0.15MG;0.01MG,N/A	N204061 001	Mar 28, 2013	Mar	NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1			LUPIN LTD	0.02MG;0.1MG	A091425 001	Jan 18, 2013	Jan	NEWA
-----	--	--	-----------	--------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

@	WARNER CHILCOTT LLC	0.005MG;1MG	N021065 002	Oct 15, 1999	Jan	DISC
---	---------------------	-------------	-------------	--------------	-----	------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

+	BARR LABS INC	0.005MG;1MG	A076221 001	Nov 06, 2009	Jan	CRLD
---	---------------	-------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ESTARYLLA

AB			SANDOZ	0.035MG;0.25MG	A090794 001	Jan 30, 2013	Jan	NEWA
----	--	--	--------	----------------	-------------	--------------	-----	------

TRI-ESTARYLLA

AB			SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090793 001	Jan 30, 2013	Jan	NEWA
----	--	--	--------	---	-------------	--------------	-----	------

ETODOLAC

TABLET; ORAL

ETODOLAC

>D>	AB		PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Mar	DISC
>A>		@		400MG	A074819 001	Feb 28, 1997	Mar	DISC
>D>	AB			500MG	A074819 002	Apr 28, 1998	Mar	DISC
>A>		@		500MG	A074819 002	Apr 28, 1998	Mar	DISC

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE

>A>	AP	AKORN INC	10MG/ML	A076324 001	Nov 27, 2002	Mar	CAHN
>D>	AP	CLARIS LIFESCIENCES	10MG/ML	A076324 001	Nov 27, 2002	Mar	CAHN
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)							
>A>	AP	AKORN INC	10MG/ML	A076322 001	Nov 27, 2002	Mar	CAHN
>D>	AP	CLARIS LIFESCIENCES	10MG/ML	A076322 001	Nov 27, 2002	Mar	CAHN

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

MUTUAL PHARM CO INC 35MG

				N022418 001	Aug 14, 2009	Feb	CAHN
--	--	--	--	-------------	--------------	-----	------

+ 105MG

				N022418 002	Aug 14, 2009	Feb	CAHN
--	--	--	--	-------------	--------------	-----	------

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM

>D>	AB	IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557 001	Aug 29, 1988	Mar	DISC
>A>		@	EQ 600MG BASE	A072557 001	Aug 29, 1988	Mar	DISC
>D>	AB	+ MYLAN	EQ 600MG BASE	A072267 001	Aug 17, 1988	Mar	CTEC
>A>		+ MYLAN PHARMS INC	EQ 600MG BASE	A072267 001	Aug 17, 1988	Mar	CTEC

FENTANYL CITRATE

TABLET; BUCCAL, SUBLINGUAL

FENTORA

AB		CEPHALON	EQ 0.1MG BASE	N021947 001	Sep 25, 2006	Feb	CDFR
AB			EQ 0.2MG BASE	N021947 002	Sep 25, 2006	Feb	CDFR
		@	EQ 0.3MG BASE	N021947 006	Mar 02, 2007	Feb	CDFR
AB		+	EQ 0.4MG BASE	N021947 003	Sep 25, 2006	Feb	CDFR
AB			EQ 0.6MG BASE	N021947 004	Sep 25, 2006	Feb	CDFR
AB			EQ 0.8MG BASE	N021947 005	Sep 25, 2006	Feb	CDFR

FERUMOXNIL

SUSPENSION; ORAL

GASTROMARK

@ AMAG PHARMS INC EQ 0.175MG IRON/ML

				N020410 001	Dec 06, 1996	Feb	DISC
--	--	--	--	-------------	--------------	-----	------

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

>D>	AB	TARO PHARM INDS	50MG/5ML	A076918 001	Dec 18, 2006	Mar	DISC
>A>		@	50MG/5ML	A076918 001	Dec 18, 2006	Mar	DISC
>D>	AB		200MG/5ML	A076918 002	Dec 18, 2006	Mar	DISC
>A>		@	200MG/5ML	A076918 002	Dec 18, 2006	Mar	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP		+ FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393 001	Oct 15, 2007	Jan	CRLD
AP		TEVA PARENTERAL	50MG/2ML (25MG/ML)	A076661 001	Apr 28, 2004	Jan	CRLD

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

+	FEINSTEIN	20-300mCi/ML	N021870 002	Nov 21, 2008	Jan	CFTG
	HOUSTON CYCLOTRON	20-500mCi/ML	A203665 001	Feb 14, 2013	Jan	NEWA

FLUOCINONIDE

CREAM; TOPICAL

LIDEX

@ CNTY LINE PHARMS	0.05%	N016908 002		Jan	CAHN
--------------------	-------	-------------	--	-----	------

LIDEX-E

@ CNTY LINE PHARMS	0.05%	N016908 003		Jan	CAHN
--------------------	-------	-------------	--	-----	------

GEL; TOPICAL

FLUOCINONIDE

AB	+	TARO	0.05%	A074935 001	Jul 29, 1997	Jan	CRLD
----	---	------	-------	-------------	--------------	-----	------

LIDEX

@ CNTY LINE PHARMS	0.05%	N017373 001		Jan	CAHN
--------------------	-------	-------------	--	-----	------

OINTMENT; TOPICAL

FLUOCINONIDE

AB	+	TARO	0.05%	A075008 001	Jun 30, 1999	Jan	CRLD
----	---	------	-------	-------------	--------------	-----	------

LIDEX

@ CNTY LINE PHARMS	0.05%	N016909 002		Jan	CAHN
--------------------	-------	-------------	--	-----	------

SOLUTION; TOPICAL

FLUOCINONIDE

AT	+	TARO	0.05%	A074799 001	Dec 31, 1996	Jan	CRLD
----	---	------	-------	-------------	--------------	-----	------

LIDEX

@ MEDICIS	0.05%	N018849 001	Apr 06, 1984	Jan	DISC
-----------	-------	-------------	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	+	MYLAN LLC	500MG/10ML (50MG/ML)	A040743 002	Apr 26, 2007	Feb	CAHN
----	---	-----------	----------------------	-------------	--------------	-----	------

AP	+		1GM/20ML (50MG/ML)	A040743 001	Apr 26, 2007	Feb	CAHN
----	---	--	--------------------	-------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1	BEIJING DOUBLE CRANE	EQ 10MG BASE	A076165 001	Feb 01, 2002	Mar	CAHN
-----	-----	----------------------	--------------	-------------	--------------	-----	------

>D>	AB1		EQ 20MG BASE	A076165 002	Feb 01, 2002	Mar	CAHN
-----	-----	--	--------------	-------------	--------------	-----	------

>D>	AB1	CARLSBAD	EQ 10MG BASE	A076022 001	Jan 30, 2002	Mar	DISC
-----	-----	----------	--------------	-------------	--------------	-----	------

>A>	@		EQ 10MG BASE	A076022 001	Jan 30, 2002	Mar	DISC
-----	---	--	--------------	-------------	--------------	-----	------

>D>	AB1		EQ 20MG BASE	A076022 002	Jan 30, 2002	Mar	DISC
-----	-----	--	--------------	-------------	--------------	-----	------

>A>	@		EQ 20MG BASE	A076022 002	Jan 30, 2002	Mar	DISC
-----	---	--	--------------	-------------	--------------	-----	------

>A>	AB1	CR DOUBLE CRANE	EQ 10MG BASE	A076165 001	Feb 01, 2002	Mar	CAHN
-----	-----	-----------------	--------------	-------------	--------------	-----	------

>A>	AB1		EQ 20MG BASE	A076165 002	Feb 01, 2002	Mar	CAHN
-----	-----	--	--------------	-------------	--------------	-----	------

@ WOCKHARDT LTD	EQ 10MG BASE	A078143 001	Jan 16, 2008	Feb	DISC
-----------------	--------------	-------------	--------------	-----	------

@	EQ 20MG BASE	A078143 002	Jan 16, 2008	Feb	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 40MG BASE	A078143 003	Jan 16, 2008	Feb	DISC
---	--------------	-------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

>A>	AB	TEVA PHARMS	EQ 25MG BASE;EQ 3MG BASE	A202074 001	Mar 25, 2013	Mar	NEWA
-----	----	-------------	--------------------------	-------------	--------------	-----	------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

>A>		FLUVOXAMINE MALEATE							
>A>	AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013	Mar	NEWA	
>A>	AB		150MG	A091476	002	Mar 13, 2013	Mar	NEWA	
		LUVOX CR							
>D>		JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Mar	CFTG	
>A>	AB		100MG	N022033	001	Feb 28, 2008	Mar	CFTG	
>D>	+		150MG	N022033	002	Feb 28, 2008	Mar	CFTG	
>A>	AB	+	150MG	N022033	002	Feb 28, 2008	Mar	CFTG	

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

>D>	AB	WATSON LABS	10MG	A076987	001	Dec 23, 2004	Mar	DISC	
>A>	@		10MG	A076987	001	Dec 23, 2004	Mar	DISC	
>D>	AB		20MG	A076987	002	Dec 23, 2004	Mar	DISC	
>A>	@		20MG	A076987	002	Dec 23, 2004	Mar	DISC	
>D>	AB		40MG	A076987	003	Dec 23, 2004	Mar	DISC	
>A>	@		40MG	A076987	003	Dec 23, 2004	Mar	DISC	

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@ INTL MEDICATION

10MG/ML

N018025 001

Jan DISC

TABLET; ORAL

FUROSEMIDE

@ DAVA PHARMS INC

20MG

N018415 001

Jul 27, 1982 Feb DISC

@

40MG

N018415 002

Jul 27, 1982 Feb DISC

@

80MG

N018415 003

Nov 26, 1984 Feb DISC

>A> GADOTERATE MEGLUMINE

>A> SOLUTION; INTRAVENOUS

>A> DOTAREM

>A> + GUERBET 37.69GM/100ML (376.9MG/ML)

N204781 001

Mar 20, 2013 Mar NEWA

>A> + 3.769GM/10ML (376.9MG/ML)

N204781 002

Mar 20, 2013 Mar NEWA

>A> + 5.6535GM/15ML (376.9MG/ML)

N204781 003

Mar 20, 2013 Mar NEWA

>A> + 7.538GM/20ML (376.9MG/ML)

N204781 004

Mar 20, 2013 Mar NEWA

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

BAYER HLTHCARE

2.72145GM/15ML (181.43MG/ML)

N022090 002

Feb 04, 2013 Feb NEWA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@ COREPHARMA

1MG

A077274 001

Oct 06, 2005 Feb DISC

@

2MG

A077274 002

Oct 06, 2005 Feb DISC

@

4MG

A077274 003

Oct 06, 2005 Feb DISC

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+ HYPERION THERAP INC 1.1GM/ML

N203284 001

Feb 01, 2013 Feb NEWA

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

>D>	AA	COREPHARMA	1MG	A040568 001	Dec 22, 2004	Mar	DISC
>A>		@	1MG	A040568 001	Dec 22, 2004	Mar	DISC
>D>	AA		2MG	A040568 002	Dec 22, 2004	Mar	DISC
>A>		@	2MG	A040568 002	Dec 22, 2004	Mar	DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

	@	EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008	Feb	DISC
--	---	--------------	-------------------------------------	-------------	--------------	-----	------

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

>D>	AB	TARO	0.05%	A076994 001	Dec 16, 2004	Mar	DISC
>A>		@	0.05%	A076994 001	Dec 16, 2004	Mar	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

>A>	AP	NAVINTA LLC	20MG/ML	A202938 001	Mar 28, 2013	Mar	NEWA
-----	----	-------------	---------	-------------	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	AA	ACTAVIS PHARMA	10MG	A091679 001	Mar 04, 2013	Feb	NEWA
	AA		25MG	A091679 002	Mar 04, 2013	Feb	NEWA
	AA		50MG	A091679 003	Mar 04, 2013	Feb	NEWA
	AA		100MG	A091679 004	Mar 04, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	WATSON LABS	25MG	A081189 001	Jan 24, 1992	Mar	DISC
>A>		@	25MG	A081189 001	Jan 24, 1992	Mar	DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

	AB	AUROBINDO PHARMA LTD	12.5MG;150MG	A203630 001	Feb 22, 2013	Feb	NEWA
	AB		12.5MG;300MG	A203630 002	Feb 22, 2013	Feb	NEWA
	AB	LUPIN LTD	12.5MG;150MG	A201524 001	Feb 27, 2013	Feb	NEWA
	AB		12.5MG;300MG	A201524 002	Feb 27, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

	AB	IPCA LABS LTD	12.5MG;50MG	A201682 001	Mar 01, 2013	Feb	NEWA
	AB		12.5MG;100MG	A201682 002	Mar 01, 2013	Feb	NEWA
	AB		25MG;100MG	A201682 003	Mar 01, 2013	Feb	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524 001	Mar 12, 2013	Mar	NEWA
>A>	AB		12.5MG;EQ 20MG BASE	A091524 002	Mar 12, 2013	Mar	NEWA
>A>	AB		25MG;EQ 20MG BASE	A091524 003	Mar 12, 2013	Mar	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	@ WATSON LABS	50MG;75MG	A071969 001	Apr 17, 1988	Jan	DISC
--	---------------	-----------	-------------	--------------	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	ALEMBIC LTD	12.5MG;80MG	A201662 001	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;160MG	A201662 002	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;320MG	A201662 003	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;160MG	A201662 004	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;320MG	A201662 005	Mar 21, 2013	Mar	NEWA
>A>	AB	APOTEX INC	12.5MG;80MG	A203026 001	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;160MG	A203026 002	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;320MG	A203026 003	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;160MG	A203026 004	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;320MG	A203026 005	Mar 21, 2013	Mar	NEWA
>A>	AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519 001	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;160MG	A202519 002	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;320MG	A202519 003	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;160MG	A202519 004	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;320MG	A202519 005	Mar 21, 2013	Mar	NEWA
>A>	AB	LUPIN LTD	12.5MG;80MG	A078946 003	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;160MG	A078946 004	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;320MG	A078946 001	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;160MG	A078946 005	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;320MG	A078946 002	Mar 21, 2013	Mar	NEWA
>A>	AB	WATSON LABS INC	12.5MG;80MG	A091519 001	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;160MG	A091519 002	Mar 21, 2013	Mar	NEWA
>A>	AB		12.5MG;320MG	A091519 003	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;160MG	A091519 004	Mar 21, 2013	Mar	NEWA
>A>	AB		25MG;320MG	A091519 005	Mar 21, 2013	Mar	NEWA

HYDROCORTISONE

LOTION; TOPICAL

STIE-CORT

	@ PERRIGO CO	1%	A089066 001	Nov 25, 1985	Feb	DISC
--	--------------	----	-------------	--------------	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE

>D>	AT	TARO	2.5%	A040310 001	Dec 29, 2000	Mar	DISC
>A>		@	2.5%	A040310 001	Dec 29, 2000	Mar	DISC

HYDROCORTISONE ACETATE

>D>		PASTE; TOPICAL					
>D>		ORABASE HCA					
>D>		COLGATE	0.5%	A083205 001		Mar	DISC
>A>		@	0.5%	A083205 001		Mar	DISC

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

@	FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001	Feb	DISC
+	TARO	0.2%	A075043 001	Aug 25, 1998	Feb	CRLD
	WESTCORT					
@	RANBAXY	0.2%	N018726 001	Aug 08, 1983	Feb	DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

	MALLINCKRODT INC	16MG	N021217 003	Mar 01, 2010	Jan	CRLD
+		32MG	N021217 004	Aug 24, 2012	Jan	CRLD

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

>D>	AB	PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Mar	DISC
>A>		@	10MG	A040753 001	Feb 28, 2008	Mar	DISC
>D>	AB		25MG	A040752 001	Feb 28, 2008	Mar	DISC
>A>		@	25MG	A040752 001	Feb 28, 2008	Mar	DISC
>D>	AB		50MG	A040751 001	Feb 28, 2008	Mar	DISC
>A>		@	50MG	A040751 001	Feb 28, 2008	Mar	DISC

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

>A>		@ ICEUTICA OPERATIONS	25MG	N016059 001		Mar	CAHN
>A>		@	50MG	N016059 002		Mar	CAHN
>D>		@ IROKO PHARMS	25MG	N016059 001		Mar	CAHN
>D>		@	50MG	N016059 002		Mar	CAHN

INDOMETHACIN

>A>	AB	SUN PHARM INDS INC	25MG	A091401 001	Mar 28, 2013	Mar	NEWA
>A>	AB		50MG	A091401 002	Mar 28, 2013	Mar	NEWA

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D>	AN	TEVA PHARMS	0.02%	A075313 001	Feb 07, 2000	Mar	DISC
>A>		@ TEVA PHARMS USA	0.02%	A075313 001	Feb 07, 2000	Mar	DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

>A>		LUITPOLD	EQ 65MG BASE/3.25ML (EQ 20MG/ML)	N021135 005	Mar 29, 2013	Mar	NEWA
-----	--	----------	----------------------------------	-------------	--------------	-----	------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

>D>	AP	INTL MEDICATION	0.2MG/ML	A083724 001		Mar	DISC
>A>		@	0.2MG/ML	A083724 001		Mar	DISC
		ISUPREL					
>D>	AP	+ HOSPIRA	0.2MG/ML	N010515 001		Mar	CTEC
>A>		+	0.2MG/ML	N010515 001		Mar	CTEC

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

>D>	AB	VALEANT INTL	5MG	N012093 007	Jul 29, 1988	Mar	CAHN
>D>	AB		10MG	N012093 002	Jul 29, 1988	Mar	CAHN
>D>	AB		20MG	N012093 006	Jul 29, 1988	Mar	CAHN
>D>	AB	+	30MG	N012093 005	Jul 29, 1988	Mar	CAHN
>D>		+	40MG	N012093 001	Jul 29, 1988	Mar	CAHN
>A>	AB	VALEANT PHARM NORTH	5MG	N012093 007	Jul 29, 1988	Mar	CAHN
>A>	AB		10MG	N012093 002	Jul 29, 1988	Mar	CAHN
>A>	AB		20MG	N012093 006	Jul 29, 1988	Mar	CAHN
>A>	AB	+	30MG	N012093 005	Jul 29, 1988	Mar	CAHN
>A>		+	40MG	N012093 001	Jul 29, 1988	Mar	CAHN

ISOSORBIDE DINITRATE

@ PAR PHARM

5MG

A086923 001 Mar 12, 1987 Feb DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

	BX	RANBAXY	10MG	N021951 001	May 25, 2012	Feb	CAHN
	BX		20MG	N021951 002	May 25, 2012	Feb	CAHN
	BX		30MG	N021951 003	May 25, 2012	Feb	CAHN
	BX		40MG	N021951 004	May 25, 2012	Feb	CAHN
>A>		ZENATANE					
>A>	AB	DR REDDYS LABS LTD	10MG	A202099 001	Mar 25, 2013	Mar	NEWA
>A>	AB		20MG	A202099 002	Mar 25, 2013	Mar	NEWA
>A>	AB		40MG	A202099 003	Mar 25, 2013	Mar	NEWA

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	+	SANDOZ	200MG	A075113 002	Aug 04, 1998	Jan	CRLD
		TRANDATE					
		@ PROMETHEUS LABS	100MG	N018716 001	May 24, 1985	Jan	DISC
		@	200MG	N018716 002	Aug 01, 1984	Jan	DISC

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

>D>	AB	+	GLAXOSMITHKLINE	25MG	N020241 005	Dec 27, 1994	Mar	CAHN
>D>		@		50MG	N020241 006	Dec 27, 1994	Mar	CAHN
>D>	AB			100MG	N020241 001	Dec 27, 1994	Mar	CAHN
>D>	AB			150MG	N020241 002	Dec 27, 1994	Mar	CAHN
>D>	AB			200MG	N020241 003	Dec 27, 1994	Mar	CAHN
>D>		@		250MG	N020241 004	Dec 27, 1994	Mar	CAHN
>A>	AB	+	GLAXOSMITHKLINE LLC	25MG	N020241 005	Dec 27, 1994	Mar	CAHN
>A>		@		50MG	N020241 006	Dec 27, 1994	Mar	CAHN
>A>	AB			100MG	N020241 001	Dec 27, 1994	Mar	CAHN
>A>	AB			150MG	N020241 002	Dec 27, 1994	Mar	CAHN
>A>	AB			200MG	N020241 003	Dec 27, 1994	Mar	CAHN
>A>		@		250MG	N020241 004	Dec 27, 1994	Mar	CAHN

TABLET, CHEWABLE; ORAL

LAMICTAL CD

>D>	AB	GLAXOSMITHKLINE	2MG	N020764 004	Sep 08, 2000	Mar	CAHN
>D>	AB		5MG	N020764 001	Aug 24, 1998	Mar	CAHN

TABLET, CHEWABLE; ORAL

LAMICTAL CD

>D>	AB	+	GLAXOSMITHKLINE	25MG	N020764	002	Aug 24,	1998	Mar	CAHN
>D>			@	100MG	N020764	003	Aug 24,	1998	Mar	CAHN
>A>	AB		GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08,	2000	Mar	CAHN
>A>	AB			5MG	N020764	001	Aug 24,	1998	Mar	CAHN
>A>	AB	+		25MG	N020764	002	Aug 24,	1998	Mar	CAHN
>A>			@	100MG	N020764	003	Aug 24,	1998	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

>A>	AB		GLAXOSMITHKLINE LLC	25MG	N022115	001	May 29,	2009	Mar	CAHN
>A>	AB	+		50MG	N022115	002	May 29,	2009	Mar	CAHN
>A>	AB			100MG	N022115	003	May 29,	2009	Mar	CAHN
>A>	AB			200MG	N022115	004	May 29,	2009	Mar	CAHN
>A>	AB			250MG	N022115	006	Jun 21,	2011	Mar	CAHN
>A>	AB			300MG	N022115	005	Apr 14,	2010	Mar	CAHN
>D>	AB		SMITHKLINE BEECHAM	25MG	N022115	001	May 29,	2009	Mar	CAHN
>D>	AB	+		50MG	N022115	002	May 29,	2009	Mar	CAHN
>D>	AB			100MG	N022115	003	May 29,	2009	Mar	CAHN
>D>	AB			200MG	N022115	004	May 29,	2009	Mar	CAHN
>D>	AB			250MG	N022115	006	Jun 21,	2011	Mar	CAHN
>D>	AB			300MG	N022115	005	Apr 14,	2010	Mar	CAHN

LAMOTRIGINE

	AB		PAR PHARM	25MG	A201791	001	Jan 18,	2013	Jan	NEWA
	AB			50MG	A201791	002	Jan 18,	2013	Jan	NEWA
	AB			100MG	A201791	003	Jan 18,	2013	Jan	NEWA
	AB			200MG	A201791	004	Jan 18,	2013	Jan	NEWA
	AB			250MG	A201791	005	Jan 18,	2013	Jan	NEWA
	AB			300MG	A201791	006	Jan 18,	2013	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

LAMICTAL ODT

>A>			GLAXOSMITHKLINE LLC	25MG	N022251	001	May 08,	2009	Mar	CAHN
>A>		+		50MG	N022251	002	May 08,	2009	Mar	CAHN
>A>				100MG	N022251	003	May 08,	2009	Mar	CAHN
>A>				200MG	N022251	004	May 08,	2009	Mar	CAHN
>D>			SMITHKLINE BEECHAM	25MG	N022251	001	May 08,	2009	Mar	CAHN
>D>		+		50MG	N022251	002	May 08,	2009	Mar	CAHN
>D>				100MG	N022251	003	May 08,	2009	Mar	CAHN
>D>				200MG	N022251	004	May 08,	2009	Mar	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT			DR REDDYS LABS LTD	0.005%	A202077	001	Feb 11,	2013	Jan	NEWA
----	--	--	--------------------	--------	---------	-----	---------	------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

>D>	AP		TEVA PARENTERAL	EQ 100MG BASE/VIAL	A081277	001	Sep 28,	1993	Mar	CAHN
>D>	AP			EQ 350MG BASE/VIAL	A040174	001	Jun 12,	1997	Mar	CAHN
>A>	AP		TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28,	1993	Mar	CAHN
>A>	AP			EQ 350MG BASE/VIAL	A040174	001	Jun 12,	1997	Mar	CAHN

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

>D>	AP	TEVA PARENTERAL	1MG/0.2ML	A075471 001	Oct 25, 2000	Mar	CAHN
>A>	AP	TEVA PHARMS USA	1MG/0.2ML	A075471 001	Oct 25, 2000	Mar	CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

>A>	AN	DEY	EQ 0.0103% BASE	A077800 001	Mar 15, 2013	Mar	NEWA
>A>	AN		EQ 0.021% BASE	A077800 002	Mar 15, 2013	Mar	NEWA
>A>	AN		EQ 0.042% BASE	A077800 003	Mar 15, 2013	Mar	NEWA

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

AA		HETERO DRUGS LTD	100MG/ML	A203052 001	Feb 28, 2013	Feb	NEWA
----	--	------------------	----------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

>D>	AB	SANDOZ	500MG	A091668 001	Nov 01, 2012	Mar	DISC
>A>		@	500MG	A091668 001	Nov 01, 2012	Mar	DISC
>D>	AB		750MG	A091668 002	Nov 01, 2012	Mar	DISC
>A>		@	750MG	A091668 002	Nov 01, 2012	Mar	DISC
	AB	VINTAGE PHARMS LLC	500MG	A202533 001	Jul 20, 2012	Jan	NEWA
	AB		750MG	A202533 002	Jul 20, 2012	Jan	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A>	AB	SANDOZ	5MG	A090486 001	Mar 26, 2013	Mar	NEWA
	AB	SUN PHARMA GLOBAL	5MG	A090362 001	Jan 31, 2013	Jan	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP		AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328 001	Jan 24, 2013	Jan	NEWA
AP			EQ 750MG/30ML (EQ 25MG/ML)	A202328 002	Jan 24, 2013	Jan	NEWA
AP		EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590 001	Jan 24, 2013	Jan	NEWA
AP			EQ 750MG/30ML (EQ 25MG/ML)	A202590 002	Jan 24, 2013	Jan	NEWA

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

SKYLA

+		BAYER HLTHCARE	13.5MG	N203159 001	Jan 09, 2013	Jan	NEWA
---	--	----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LEVONORGESTREL

AB		LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013	Jan	NEWA
AB		NOVEL LABS INC	1.5MG	A202508 001	Feb 22, 2013	Feb	NEWA

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVOXYL

>D>	AB1, AB3	KING PHARMS	0.05MG	N021301 002	May 25, 2001	Mar	CAHN
-----	-------------	-------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LEVOXYL

>D>	AB1, AB3	KING PHARMS	0.075MG	N021301 003	May 25, 2001	Mar	CAHN
>D>	AB1, AB3		0.088MG	N021301 004	May 25, 2001	Mar	CAHN
>D>	AB1, AB3		0.1MG	N021301 005	May 25, 2001	Mar	CAHN
>D>	AB1, AB3		0.112MG	N021301 006	May 25, 2001	Mar	CAHN
>D>	AB1, AB3		0.125MG	N021301 007	May 25, 2001	Mar	CAHN
>D>	AB1, AB3		0.137MG	N021301 008	May 25, 2001	Mar	CAHN
>D>	AB1, AB3		0.15MG	N021301 009	May 25, 2001	Mar	CAHN
>D>	AB1, AB3		0.175MG	N021301 010	May 25, 2001	Mar	CAHN
>D>	AB1, + AB3		0.2MG	N021301 011	May 25, 2001	Mar	CAHN
>D>	@		0.3MG	N021301 012	May 25, 2001	Mar	CAHN
>D>	AB1, AB3	KING PHARMS R AND D	0.025MG	N021301 001	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.025MG	N021301 001	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.05MG	N021301 002	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.075MG	N021301 003	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.088MG	N021301 004	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.1MG	N021301 005	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.112MG	N021301 006	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.125MG	N021301 007	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.137MG	N021301 008	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.15MG	N021301 009	May 25, 2001	Mar	CAHN
>A>	AB1, AB3		0.175MG	N021301 010	May 25, 2001	Mar	CAHN
>A>	AB1, + AB3		0.2MG	N021301 011	May 25, 2001	Mar	CAHN
>A>	@		0.3MG	N021301 012	May 25, 2001	Mar	CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

>D>	AP	LUITPOLD	2%	A083198 001		Mar	DISC
>A>	@		2%	A083198 001		Mar	DISC
>A>	AP	AUROBINDO PHARMA LTD	1%	A203082 001	Mar 14, 2013	Mar	NEWA
>A>	AP		1%	A203040 001	Mar 14, 2013	Mar	NEWA
>A>	AP		2%	A203082 002	Mar 14, 2013	Mar	NEWA
>A>	AP		2%	A203040 002	Mar 14, 2013	Mar	NEWA

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

>D>	AB	KING PHARMS	EQ 0.005MG BASE	N010379 001		Mar	CAHN
>D>	AB		EQ 0.025MG BASE	N010379 002		Mar	CAHN
>D>	AB	+	EQ 0.05MG BASE	N010379 003		Mar	CAHN
>A>	AB	KING PHARMS R AND D	EQ 0.005MG BASE	N010379 001		Mar	CAHN

TABLET; ORAL

CYTOMEL

>A>	AB	KING PHARMS R AND D	EQ 0.025MG BASE	N010379 002		Mar	CAHN
>A>	AB	+	EQ 0.05MG BASE	N010379 003		Mar	CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

@ SANDOZ	2.5MG	A075999 001	Jul 01, 2002	Jan	CAHN
@	5MG	A075999 002	Jul 01, 2002	Jan	CAHN
@	10MG	A075999 003	Jul 01, 2002	Jan	CAHN
@	20MG	A075999 004	Jul 01, 2002	Jan	CAHN
@	30MG	A075999 005	Jul 01, 2002	Jan	CAHN
@	40MG	A075999 006	Jul 01, 2002	Jan	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

@ APOTEX INC	300MG	A076795 001	Nov 22, 2004	Feb	DISC
--------------	-------	-------------	--------------	-----	------

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	LUPIN LTD	2MG/ML	A091407 001	Feb 19, 2013	Feb	NEWA
----	-----------	--------	-------------	--------------	-----	------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

>A>	AB	ACTAVIS GRP PTC	25MG	A090382 001	Oct 06, 2010	Mar	CAHN
>A>	AB		50MG	A090382 002	Oct 06, 2010	Mar	CAHN
>A>	AB		100MG	A090382 003	Oct 06, 2010	Mar	CAHN
>D>	AB	ACTAVIS INC	25MG	A090382 001	Oct 06, 2010	Mar	CAHN
>D>	AB		50MG	A090382 002	Oct 06, 2010	Mar	CAHN
>D>	AB		100MG	A090382 003	Oct 06, 2010	Mar	CAHN

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	+	CARLSBAD	40MG	A075991 003	Jun 05, 2002	Feb	CRLD
		MEVACOR					
		@ MERCK	20MG	N019643 003	Aug 31, 1987	Feb	DISC
		@	40MG	N019643 004	Dec 14, 1988	Feb	DISC

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE

AB		PAR FORM	5%	A201511 001	Feb 12, 2013	Jan	NEWA
		SULFAMYLLON					
AB	+	MYLAN LLC	5%	N019832 003	Jun 05, 1998	Jan	CFTG

MAGNESIUM SULFATE, POTASSIUM SULFATE, SODIUM SULFATE; POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

SOLUTION, FOR SOLUTION; ORAL, ORAL

SUCLEAR

+	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595 001	Jan 18, 2013	Jan	NEWA
---	----------------	---	-------------	--------------	-----	------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 20%

@ B BRAUN

20GM/100ML

N014738 001

Jan DISC

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

>A> MECAMYLAMINE HYDROCHLORIDE

>A> NEXGEN PHARMA 2.5MG

A204054 001 Mar 19, 2013 Mar NEWA

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB CYPRESS PHARM

250MG

A090359 001 Feb 05, 2013 Jan NEWA

MELOXICAM

TABLET; ORAL

MELOXICAM

>D> AB BEIJING DOUBLE CRANE 7.5MG

A078039 001 Dec 14, 2006 Mar CAHN

>D> AB 15MG

A078039 002 Dec 14, 2006 Mar CAHN

@ COREPHARMA 7.5MG

A077930 001 Jul 19, 2006 Feb DISC

@ 15MG

A077930 002 Jul 19, 2006 Feb DISC

>A> AB CR DOUBLE CRANE 7.5MG

A078039 001 Dec 14, 2006 Mar CAHN

>A> AB 15MG

A078039 002 Dec 14, 2006 Mar CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ TARO

200MG

A200998 001 May 23, 2011 Jan DISC

@ 400MG

A200998 002 May 23, 2011 Jan DISC

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+ WARNER CHILCOTT LLC 400MG

N204412 001 Feb 01, 2013 Feb NEWA

SUPPOSITORY; RECTAL

CANASA

+ APTALIS PHARMA US 1GM

N021252 002 Nov 05, 2004 Feb CRLD

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

@ NOVEX

10MG/5ML

A075235 001 Jan 27, 2000 Feb DISC

+ SILARX 10MG/5ML

A073632 001 Jul 22, 1992 Feb CTEC

TABLET; ORAL

METAPROTERENOL SULFATE

>D> AB PAR PHARM 10MG

A072024 001 Jun 28, 1988 Mar CTEC

>A> 10MG

A072024 001 Jun 28, 1988 Mar CTEC

>D> AB + 20MG

A072025 001 Jun 28, 1988 Mar CTEC

>A> + 20MG

A072025 001 Jun 28, 1988 Mar CTEC

>D> AB WATSON LABS 10MG

A073013 001 Jan 31, 1991 Mar DISC

>A> @ 10MG

A073013 001 Jan 31, 1991 Mar DISC

>D> AB 20MG

A072795 001 Jan 31, 1991 Mar DISC

>A> @ 20MG

A072795 001 Jan 31, 1991 Mar DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	SANDOZ	500MG	A075965 001	Jan 25, 2002	Mar	DISC
>A>		@	500MG	A075965 001	Jan 25, 2002	Mar	DISC
>D>	AB		850MG	A075965 002	Jan 25, 2002	Mar	DISC
>A>		@	850MG	A075965 002	Jan 25, 2002	Mar	DISC
>D>	AB		1GM	A075965 003	Jan 25, 2002	Mar	DISC
>A>		@	1GM	A075965 003	Jan 25, 2002	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>D>	AB1	WATSON LABS INC	500MG	A076818 001	Dec 14, 2004	Mar	DISC
>A>		@	500MG	A076818 001	Dec 14, 2004	Mar	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	500MG;EQ 15MG BASE	A200823 001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A200823 002	Feb 13, 2013	Jan	NEWA
AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001 001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A202001 002	Feb 13, 2013	Jan	NEWA

METHADONE HYDROCHLORIDE

>D> TABLET; ORAL

>D> METHADONE HYDROCHLORIDE

>D>	AA	MALLINCKRODT	40MG	A077142 001	Jul 12, 2005	Mar	CDFR
>D>	AA	+ ROXANE	40MG	N017058 001		Mar	CDFR
>D>	AA	SANDOZ	40MG	A075082 001	Mar 25, 1998	Mar	CDFR
>D>		METHADOSE					
>D>	AA	MALLINCKRODT	40MG	A074184 001	Apr 29, 1993	Mar	CDFR

>A> TABLET, FOR SUSPENSION; ORAL

>A> METHADONE HYDROCHLORIDE

>A>	AA	MALLINCKRODT INC	40MG	A077142 001	Jul 12, 2005	Mar	CDFR
>A>	AA	+ ROXANE	40MG	N017058 001		Mar	CDFR
>A>	AA	SANDOZ	40MG	A075082 001	Mar 25, 1998	Mar	CDFR
>A>		METHADOSE					
>A>	AA	MALLINCKRODT	40MG	A074184 001	Apr 29, 1993	Mar	CDFR

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

		@ AUSTARPHARMA LLC	500MG	A200958 001	Oct 21, 2011	Jan	DISC
		@	750MG	A200958 002	Oct 21, 2011	Jan	DISC
AA		PRINSTON INC	500MG	A086989 001		Feb	CMFD
AA			750MG	A086988 001		Feb	CAHN
		@ SOLCO HLTHCARE	500MG	A086989 001		Jan	DISC

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

+	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Jan	CTEC
	@ WATSON LABS	5MG	A088724 001	Sep 06, 1984	Jan	DISC

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METHYLIN ER
MALLINCKRODT INC 10MG

A075629 001 May 09, 2000 Feb CTEC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HYDROCHLORIDE
@ TEVA PARENTERAL EQ 5MG BASE/ML

A073135 001 Nov 27, 1991 Feb DISC

METOLAZONE

TABLET; ORAL
METOLAZONE

>D> AB TEVA 2.5MG
>A> @ 2.5MG

A076600 001 Jan 06, 2004 Mar DISC

A076600 001 Jan 06, 2004 Mar DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE
@ NESHER PHARMS EQ 25MG TARTRATE

A077779 001 Mar 20, 2008 Feb DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION
METOPROLOL TARTRATE

>D> AP WATSON LABS 1MG/ML
>A> @ 1MG/ML

A074032 001 Dec 21, 1993 Mar DISC

A074032 001 Dec 21, 1993 Mar DISC

TABLET; ORAL

METOPROLOL TARTRATE

>A> @ PRINSTON INC 50MG
>A> @ 100MG
>D> @ SOLCO HLTHCARE 50MG
>D> @ 100MG

A074453 001 Apr 27, 1995 Mar CAHN

A074453 002 Apr 27, 1995 Mar CAHN

A074453 001 Apr 27, 1995 Mar CAHN

A074453 002 Apr 27, 1995 Mar CAHN

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

>D> AB PLIVA 250MG
>A> AB TEVA PHARMS USA 250MG

A070027 001 Nov 06, 1984 Mar CAHN

A070027 001 Nov 06, 1984 Mar CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

@ CLARIS LIFESCIENCES EQ 1MG BASE/ML
@ EQ 5MG BASE/ML

A075637 001 Oct 31, 2000 Jan DISC

A075637 002 Oct 31, 2000 Jan DISC

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS
KYNAMRO

+ GENZYME CORP 200MG/ML (200MG/ML)

N203568 001 Jan 29, 2013 Jan NEWA

MITOXANTRONE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>D> AP ONCO THERAPIES LTD EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A201014 001 Dec 11, 2012 Mar CAIN

>A> MITOXANTRONE HYDROCHLORIDE

>A> INJECTABLE; INJECTION

>A> MITOXANTRONE HYDROCHLORIDE

>A>	AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014 001	Dec 11, 2012	Mar	CAIN
-----	----	--------------------	------------------------------------	-------------	--------------	-----	------

MUPIROCIIN CALCIUM

CREAM; TOPICAL

BACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746 001	Dec 11, 1997	Jan	CFTG
----	---	-----------------	------------	-------------	--------------	-----	------

MUPIROCIIN

AB		GLENMARK GENERICS	EQ 2% BASE	A201587 001	Jan 24, 2013	Jan	NEWA
----	--	-------------------	------------	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

>D>	AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Mar	DISC
-----	----	-------------	-------	-------------	--------------	-----	------

>A>		@	500MG	A079093 001	Feb 27, 2009	Mar	DISC
-----	--	---	-------	-------------	--------------	-----	------

>D>	AB		750MG	A079093 002	Feb 27, 2009	Mar	DISC
-----	----	--	-------	-------------	--------------	-----	------

>A>		@	750MG	A079093 002	Feb 27, 2009	Mar	DISC
-----	--	---	-------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

>D>	AB	GLAXOSMITHKLINE	EQ 1MG BASE	N020763 002	Feb 10, 1998	Mar	CAHN
-----	----	-----------------	-------------	-------------	--------------	-----	------

>D>	AB	+	EQ 2.5MG BASE	N020763 001	Feb 10, 1998	Mar	CAHN
-----	----	---	---------------	-------------	--------------	-----	------

>A>	AB	GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763 002	Feb 10, 1998	Mar	CAHN
-----	----	---------------------	-------------	-------------	--------------	-----	------

>A>	AB	+	EQ 2.5MG BASE	N020763 001	Feb 10, 1998	Mar	CAHN
-----	----	---	---------------	-------------	--------------	-----	------

NEOMYCIN SULFATE

>D> POWDER; FOR RX COMPOUNDING

>D> NEO-RX

>D>		X GEN PHARMS	100%	A061579 001		Mar	DISC
-----	--	--------------	------	-------------	--	-----	------

>A>		@	100%	A061579 001		Mar	DISC
-----	--	---	------	-------------	--	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

>D>	AB	ALVOGEN INC	25MG	N016620 003		Mar	CTEC
-----	----	-------------	------	-------------	--	-----	------

>A>			25MG	N016620 003		Mar	CTEC
-----	--	--	------	-------------	--	-----	------

	AB		25MG	N016620 003		Feb	CAHN
--	----	--	------	-------------	--	-----	------

	AB		50MG	N016620 001		Feb	CAHN
--	----	--	------	-------------	--	-----	------

	AB	+	100MG	N016620 002		Feb	CAHN
--	----	---	-------	-------------	--	-----	------

NITROFURANTOIN

>D>	AB	WATSON LABS	25MG	A073696 001	Dec 31, 1992	Mar	DISC
-----	----	-------------	------	-------------	--------------	-----	------

>A>		@	25MG	A073696 001	Dec 31, 1992	Mar	DISC
-----	--	---	------	-------------	--------------	-----	------

>D>	AB		50MG	A073696 002	Dec 31, 1992	Mar	DISC
-----	----	--	------	-------------	--------------	-----	------

>A>		@	50MG	A073696 002	Dec 31, 1992	Mar	DISC
-----	--	---	------	-------------	--------------	-----	------

>D>	AB		100MG	A073696 003	Dec 31, 1992	Mar	DISC
-----	----	--	-------	-------------	--------------	-----	------

>A>		@	100MG	A073696 003	Dec 31, 1992	Mar	DISC
-----	--	---	-------	-------------	--------------	-----	------

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

>D>	AB	+	ALMATICA	75MG; 25MG	N020064 001	Dec 24, 1991	Mar	CAHN
-----	----	---	----------	------------	-------------	--------------	-----	------

CAPSULE; ORAL

MACROBID

>A>	AB	+	ALVOGEN INC	75MG;25MG	N020064 001	Dec 24, 1991	Mar	CAHN
-----	----	---	-------------	-----------	-------------	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR

>D>	AB1	+	KEY PHARMS	0.1MG/HR	N020145 001	Apr 04, 1995	Mar	CAHN
>D>	AB1	+		0.2MG/HR	N020145 002	Apr 04, 1995	Mar	CAHN
>D>		+		0.3MG/HR	N020145 003	Apr 04, 1995	Mar	CAHN
>D>	AB1	+		0.4MG/HR	N020145 004	Apr 04, 1995	Mar	CAHN
>D>	AB1	+		0.6MG/HR	N020145 005	Apr 04, 1995	Mar	CAHN
>D>		+		0.8MG/HR	N020145 006	Apr 04, 1995	Mar	CAHN
>A>	AB1	+	MERCK SHARP DOHME	0.1MG/HR	N020145 001	Apr 04, 1995	Mar	CAHN
>A>	AB1	+		0.2MG/HR	N020145 002	Apr 04, 1995	Mar	CAHN
>A>		+		0.3MG/HR	N020145 003	Apr 04, 1995	Mar	CAHN
>A>	AB1	+		0.4MG/HR	N020145 004	Apr 04, 1995	Mar	CAHN
>A>	AB1	+		0.6MG/HR	N020145 005	Apr 04, 1995	Mar	CAHN
>A>		+		0.8MG/HR	N020145 006	Apr 04, 1995	Mar	CAHN

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

@ APOTEX INC

150MG

A076383 001 Jan 23, 2003 Feb DISC

@

300MG

A076383 002 Jan 23, 2003 Feb DISC

NORETHINDRONE

TABLET; ORAL-28

JENCYCLA

>A>	AB		LUPIN LTD	0.35MG	A091323 001	Mar 28, 2013	Mar	NEWA
-----	----	--	-----------	--------	-------------	--------------	-----	------

NYSTATIN

SUSPENSION; ORAL

NILSTAT

@ GLENMARK GENERICS

100,000 UNITS/ML

N050299 001

Feb DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP			CLARIS LIFESCIENCES	2MG/ML	A078288 001	Feb 22, 2013	Feb	NEWA
>D>	AP		LUITPOLD	EQ 2MG BASE/ML	A077582 001	Dec 26, 2006	Mar	DISC
>A>		@		EQ 2MG BASE/ML	A077582 001	Dec 26, 2006	Mar	DISC
		@	PLIVA HRVATSKA D00	EQ 2MG BASE/ML	A077544 001	Dec 26, 2006	Feb	DISC
			ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER					
		@	CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308 001	Mar 17, 2008	Jan	DISC
		@	HOSPIRA	EQ 0.64MG BASE/ML	A077348 001	Feb 01, 2007	Jan	DISC
			ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP			CLARIS LIFESCIENCES	2MG/ML	A078287 001	Feb 22, 2013	Feb	NEWA
>D>	AP		LUITPOLD	EQ 2MG BASE/ML	A077387 001	Dec 26, 2006	Mar	DISC
>A>		@		EQ 2MG BASE/ML	A077387 001	Dec 26, 2006	Mar	DISC

OSPEMIFENE

TABLET; ORAL

OSPHENA

+ SHIONOGI INC

60MG

N203505 001 Feb 26, 2013 Feb NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539 001	Jan 18, 2013	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A201539 002	Jan 18, 2013	Jan	NEWA
AP		EQ 10GM BASE/VIAL	A201538 001	Jan 18, 2013	Jan	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@ CARACO

600MG

A075844 001 Jan 03, 2002 Jan DISC

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

>D>	AB	TEVA PHARMS	150MG	A078005 001	Dec 11, 2007	Mar	DISC
>D>	AB		300MG	A078005 002	Dec 11, 2007	Mar	DISC
>D>	AB		600MG	A078005 003	Dec 11, 2007	Mar	DISC
>A>		@ TEVA PHARMS USA	150MG	A078005 001	Dec 11, 2007	Mar	DISC
>A>		@	300MG	A078005 002	Dec 11, 2007	Mar	DISC
>A>		@	600MG	A078005 003	Dec 11, 2007	Mar	DISC

OXYBUTYNIN CHLORIDE

TABLET; ORAL

OXYBUTYNIN CHLORIDE

>D>	AB	PLIVA	5MG	A071655 001	Nov 14, 1988	Mar	CAHN
>A>	AB	TEVA PHARMS USA	5MG	A071655 001	Nov 14, 1988	Mar	CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

>D>	AB	NESHER PHARMS	5MG	A077290 001	Dec 08, 2005	Mar	DISC
>A>		@	5MG	A077290 001	Dec 08, 2005	Mar	DISC
>D>	AB		10MG	A077290 002	Dec 08, 2005	Mar	DISC
>A>		@	10MG	A077290 002	Dec 08, 2005	Mar	DISC
>D>	AB		15MG	A077290 003	Dec 08, 2005	Mar	DISC
>A>		@	15MG	A077290 003	Dec 08, 2005	Mar	DISC
>D>	AB		20MG	A077290 004	Dec 08, 2005	Mar	DISC
>A>		@	20MG	A077290 004	Dec 08, 2005	Mar	DISC
>D>	AB		30MG	A077290 005	Dec 08, 2005	Mar	DISC
>A>		@	30MG	A077290 005	Dec 08, 2005	Mar	DISC

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AVANTHI INC	5MG	A203601 001	Jan 30, 2013	Jan	NEWA
AB		10MG	A203601 002	Jan 30, 2013	Jan	NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219 001	Feb 13, 2013	Jan	NEWA
----	--------------------	---------------------------------	-------------	--------------	-----	------

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ HQ SPCLT PHARMA

6MG/ML

N020262 001 Dec 29, 1992 Jan CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

>D> AP TEVA PARENTERAL 30MG/10ML (3MG/ML)

A076153 001 Mar 27, 2002 Mar CAHN

>D> AP 90MG/10ML (9MG/ML)

A076153 002 Mar 27, 2002 Mar CAHN

>A> AP TEVA PHARMS USA 30MG/10ML (3MG/ML)

A076153 001 Mar 27, 2002 Mar CAHN

>A> AP 90MG/10ML (9MG/ML)

A076153 002 Mar 27, 2002 Mar CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

>A> ABBVIE 180,000USP UNITS;36,000USP UNITS;114,000USP UNITS

N020725 005 Mar 14, 2013 Mar NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

>D> AP + TEVA PARENTERAL 2MG/ML

A072760 001 Jul 31, 1990 Mar CAHN

>A> AP + TEVA PHARMS USA 2MG/ML

A072760 001 Jul 31, 1990 Mar CAHN

PHENYLEPHRINE HYDROCHLORIDE

>A> SOLUTION/DROPS; OPHTHALMIC

>A> PHENYLEPHRINE HYDROCHLORIDE

>A> PARAGON BIOTECK 2.5%

N203510 001 Mar 21, 2013 Mar NEWA

>A> + 10%

N203510 002 Mar 21, 2013 Mar NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

>D> AP HOSPIRA 50MG/ML

A089744 001 Dec 18, 1987 Mar DISC

>A> @ 50MG/ML

A089744 001 Dec 18, 1987 Mar DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB ACCORD HLTHCARE EQ 15MG BASE

A200044 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE

A200044 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE

A200044 003 Feb 13, 2013 Jan NEWA

AB AUROBINDO PHARMA LTD EQ 15MG BASE

A200268 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE

A200268 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE

A200268 003 Feb 13, 2013 Jan NEWA

>A> AB DR REDDYS LABS LTD EQ 15MG BASE

A078383 001 Mar 12, 2013 Mar NEWA

>A> AB EQ 30MG BASE

A078383 002 Mar 12, 2013 Mar NEWA

>A> AB EQ 45MG BASE

A078383 003 Mar 12, 2013 Mar NEWA

AB MACLEODS PHARMS LTD EQ 15MG BASE

A202467 001 Feb 06, 2013 Jan NEWA

AB EQ 30MG BASE

A202467 002 Feb 06, 2013 Jan NEWA

AB EQ 45MG BASE

A202467 003 Feb 06, 2013 Jan NEWA

AB SANDOZ EQ 15MG BASE

A078670 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE

A078670 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE

A078670 003 Feb 13, 2013 Jan NEWA

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	SYNTHON PHARMS	EQ 15MG BASE	A078472 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A078472 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A078472 003	Feb 13, 2013	Jan	NEWA
AB	TORRENT PHARMS LTD	EQ 15MG BASE	A091298 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A091298 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A091298 003	Feb 13, 2013	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 15MG BASE	A202456 001	Feb 13, 2013	Jan	NEWA
AB		EQ 30MG BASE	A202456 002	Feb 13, 2013	Jan	NEWA
AB		EQ 45MG BASE	A202456 003	Feb 13, 2013	Jan	NEWA

POLYMYXIN B SULFATE

>D> POWDER; FOR RX COMPOUNDING

>D> POLY-RX

>D>	+ X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001		Mar	DISC
-----	----------------	-----------------------	-------------	--	-----	------

>A>	@	100,000,000 UNITS/BOT	A061578 001		Mar	DISC
-----	---	-----------------------	-------------	--	-----	------

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

CELGENE

+

1MG	N204026 001	Feb 08, 2013	Feb	NEWA
2MG	N204026 002	Feb 08, 2013	Feb	NEWA
3MG	N204026 003	Feb 08, 2013	Feb	NEWA
4MG	N204026 004	Feb 08, 2013	Feb	NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128 001	Feb 22, 2013	Feb	NEWA
----	---------------	-------	-------------	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB	ACTAVIS GRP PTC	0.125MG	A091254 001	Nov 30, 2010	Mar	CAHN
>A>	AB		0.25MG	A091254 002	Nov 30, 2010	Mar	CAHN
>A>	AB		0.5MG	A091254 003	Nov 30, 2010	Mar	CAHN
>A>	AB		0.75MG	A091254 004	Nov 30, 2010	Mar	CAHN
>A>	AB		1MG	A091254 005	Nov 30, 2010	Mar	CAHN
>A>	AB		1.5MG	A091254 006	Nov 30, 2010	Mar	CAHN
>D>	AB	ACTAVIS PHARMA	0.125MG	A091254 001	Nov 30, 2010	Mar	CAHN
>D>	AB		0.25MG	A091254 002	Nov 30, 2010	Mar	CAHN
>D>	AB		0.5MG	A091254 003	Nov 30, 2010	Mar	CAHN
>D>	AB		0.75MG	A091254 004	Nov 30, 2010	Mar	CAHN
>D>	AB		1MG	A091254 005	Nov 30, 2010	Mar	CAHN
>D>	AB		1.5MG	A091254 006	Nov 30, 2010	Mar	CAHN
>A>	AB	SUN PHARM INDS INC	0.125MG	A091683 001	Mar 27, 2013	Mar	NEWA
>A>	AB		0.25MG	A091683 002	Mar 27, 2013	Mar	NEWA
>A>	AB		0.5MG	A091683 003	Mar 27, 2013	Mar	NEWA
>A>	AB		0.75MG	A091683 004	Mar 27, 2013	Mar	NEWA
>A>	AB		1MG	A091683 005	Mar 27, 2013	Mar	NEWA
>A>	AB		1.5MG	A091683 006	Mar 27, 2013	Mar	NEWA

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

	AMYLIN PHARMS	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332 002	Sep 25, 2007	Jan	CAHN
		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332 003	Sep 25, 2007	Jan	CAHN
+		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332 001	Mar 16, 2005	Jan	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

>D>	AA	PHARM ASSOC	EQ 5MG BASE/5ML	A076123 001	Dec 23, 2002	Mar	DISC
>A>		@	EQ 5MG BASE/5ML	A076123 001	Dec 23, 2002	Mar	DISC
>D>	AA	WE PHARMS	EQ 15MG BASE/5ML	A075250 001	Jul 12, 2002	Mar	DISC
>A>		@	EQ 15MG BASE/5ML	A075250 001	Jul 12, 2002	Mar	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

>D>		SHIONOGI INC	EQ 10MG BASE	N021959 001	Jun 01, 2006	Mar	CFTG
>A>	AB		EQ 10MG BASE	N021959 001	Jun 01, 2006	Mar	CFTG
>D>			EQ 15MG BASE	N021959 002	Jun 01, 2006	Mar	CFTG
>A>	AB		EQ 15MG BASE	N021959 002	Jun 01, 2006	Mar	CFTG
>D>		+	EQ 30MG BASE	N021959 003	Jun 01, 2006	Mar	CFTG
>A>	AB	+	EQ 30MG BASE	N021959 003	Jun 01, 2006	Mar	CFTG
>A>		PREDNISOLONE SODIUM PHOSPHATE					
>A>	AB	MYLAN PHARMS INC	EQ 10MG BASE	A202179 001	Apr 10, 2013	Mar	NEWA
>A>	AB		EQ 15MG BASE	A202179 002	Apr 10, 2013	Mar	NEWA
>A>	AB		EQ 30MG BASE	A202179 003	Apr 10, 2013	Mar	NEWA

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

>D>	AP	+	TEVA PARENTERAL	25MG/ML	A040454 001	Aug 22, 2002	Mar	CAHN
>D>	AP	+		50MG/ML	A040454 002	Aug 22, 2002	Mar	CAHN
>A>	AP	+	TEVA PHARMS USA	25MG/ML	A040454 001	Aug 22, 2002	Mar	CAHN
>A>	AP	+		50MG/ML	A040454 002	Aug 22, 2002	Mar	CAHN

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

>D>	AB		TEVA PARENTERAL	10MG/ML	A075102 001	Jan 04, 1999	Mar	CAHN
>A>	AB		TEVA PHARMS USA	10MG/ML	A075102 001	Jan 04, 1999	Mar	CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB		GLATT AIR	60MG	A078065 001	Jan 26, 2007	Feb	CAHN
AB			80MG	A078065 002	Jan 26, 2007	Feb	CAHN
AB			120MG	A078065 003	Jan 26, 2007	Feb	CAHN
AB			160MG	A078065 004	Jan 26, 2007	Feb	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

>A>		@	TEVA WOMENS	5MG	N016012 001		Mar	CAHN
-----	--	---	-------------	-----	-------------	--	-----	------

TABLET; ORAL

VIVACTIL

>A>	@ TEVA WOMENS	10MG	N016012 002	Mar	CAHN
>D>	@ TEVA WOMENS R AND D	5MG	N016012 001	Mar	CAHN
>D>	@	10MG	N016012 002	Mar	CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACTAVIS PHARMA	EQ 25MG BASE	A201762 001	Feb 27, 2013	Feb	NEWA
AB		EQ 50MG BASE	A201762 002	Feb 27, 2013	Feb	NEWA
AB		EQ 100MG BASE	A201762 003	Feb 27, 2013	Feb	NEWA
AB		EQ 150MG BASE	A201762 004	Feb 27, 2013	Feb	NEWA
AB		EQ 200MG BASE	A201762 005	Feb 27, 2013	Feb	NEWA
AB		EQ 300MG BASE	A201762 006	Feb 27, 2013	Feb	NEWA
AB		EQ 400MG BASE	A201762 007	Feb 27, 2013	Feb	NEWA
AB	ALKEM LABS LTD	EQ 25MG BASE	A201504 001	Feb 12, 2013	Jan	NEWA
AB		EQ 50MG BASE	A201504 002	Feb 12, 2013	Jan	NEWA
AB		EQ 100MG BASE	A201504 003	Feb 12, 2013	Jan	NEWA
AB		EQ 150MG BASE	A201504 004	Feb 12, 2013	Jan	NEWA
AB		EQ 200MG BASE	A201504 005	Feb 12, 2013	Jan	NEWA
AB		EQ 300MG BASE	A201504 006	Feb 12, 2013	Jan	NEWA
AB		EQ 400MG BASE	A201504 007	Feb 12, 2013	Jan	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

>D>	AB	APOTEX	EQ 5MG BASE	A076240 001	Jan 26, 2006	Mar	DISC
>D>	AB		EQ 10MG BASE	A076240 002	Jan 26, 2006	Mar	DISC
>D>	AB		EQ 20MG BASE	A076240 003	Jan 26, 2006	Mar	DISC
>D>	AB		EQ 40MG BASE	A076240 004	Jan 26, 2006	Mar	DISC
>A>		@ APOTEX INC	EQ 5MG BASE	A076240 001	Jan 26, 2006	Mar	DISC
>A>		@	EQ 10MG BASE	A076240 002	Jan 26, 2006	Mar	DISC
>A>		@	EQ 20MG BASE	A076240 003	Jan 26, 2006	Mar	DISC
>A>		@	EQ 40MG BASE	A076240 004	Jan 26, 2006	Mar	DISC

RABEPRAZOLE SODIUM

>A>	CAPSULE, DELAYED RELEASE; ORAL					
>A>	ACIPHEX SPRINKLE					
>A>	EISAI INC	5MG	N204736 001	Mar 26, 2013	Mar	NEWA
>A>	+	10MG	N204736 002	Mar 26, 2013	Mar	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	25MG/ML	A091534 001	Feb 22, 2013	Feb	NEWA
----	----------------------	---------	-------------	--------------	-----	------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>D>	AB	WATSON LABS	EQ 150MG BASE	A077426 001	Dec 19, 2005	Mar	DISC
		@	EQ 150MG BASE	A074864 001	Oct 20, 1997	Jan	DISC
>D>	AB		EQ 300MG BASE	A077426 002	Dec 19, 2005	Mar	DISC
		@	EQ 300MG BASE	A074864 002	Oct 20, 1997	Jan	DISC
>A>		@ WATSON LABS INC	EQ 150MG BASE	A077426 001	Dec 19, 2005	Mar	DISC
>A>		@	EQ 300MG BASE	A077426 002	Dec 19, 2005	Mar	DISC

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

@ COREPHARMA

100MG

A075916 001 Nov 02, 2001 Feb DISC

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	MYLAN PHARMS INC	0.25MG	A091537 006	Feb 12, 2013	Feb	NEWA
AB	PAR PHARM	0.25MG	A077494 001	Apr 30, 2009	Feb	CTEC
>A>	AB	SUN PHARM INDS LTD	0.5MG	A078464 001	Apr 08, 2013	Mar NEWA
>A>	AB		1MG	A078464 002	Apr 08, 2013	Mar NEWA
>A>	AB		2MG	A078464 003	Apr 08, 2013	Mar NEWA
>A>	AB		3MG	A078464 004	Apr 08, 2013	Mar NEWA
>A>	AB		4MG	A078464 005	Apr 08, 2013	Mar NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

>A>	AB	CIPLA LTD	EQ 5MG BASE	A077526 001	Mar 26, 2013	Mar NEWA
>A>	AB		EQ 10MG BASE	A077526 002	Mar 26, 2013	Mar NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

@ ORGANON USA INC

10MG/ML (10MG/ML)

N020214 002 Mar 17, 1994 Jan CAHN

AP + 50MG/5ML (10MG/ML)

N020214 001 Mar 17, 1994 Jan CAHN

AP + 100MG/10ML (10MG/ML)

N020214 003 Mar 17, 1994 Jan CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

>D>	AB	+	GLAXOSMITHKLINE	EQ 0.25MG BASE	N020658 001	Sep 19, 1997	Mar CAHN
>D>	AB			EQ 0.5MG BASE	N020658 002	Sep 19, 1997	Mar CAHN
>D>	AB			EQ 1MG BASE	N020658 003	Sep 19, 1997	Mar CAHN
>D>	AB			EQ 2MG BASE	N020658 004	Sep 19, 1997	Mar CAHN
>D>	AB			EQ 3MG BASE	N020658 006	Jan 27, 1999	Mar CAHN
>D>	AB			EQ 4MG BASE	N020658 007	Jan 27, 1999	Mar CAHN
>D>	AB			EQ 5MG BASE	N020658 005	Sep 19, 1997	Mar CAHN
>A>	AB	+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658 001	Sep 19, 1997	Mar CAHN
>A>	AB			EQ 0.5MG BASE	N020658 002	Sep 19, 1997	Mar CAHN
>A>	AB			EQ 1MG BASE	N020658 003	Sep 19, 1997	Mar CAHN
>A>	AB			EQ 2MG BASE	N020658 004	Sep 19, 1997	Mar CAHN
>A>	AB			EQ 3MG BASE	N020658 006	Jan 27, 1999	Mar CAHN
>A>	AB			EQ 4MG BASE	N020658 007	Jan 27, 1999	Mar CAHN
>A>	AB			EQ 5MG BASE	N020658 005	Sep 19, 1997	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

>A>	AB	+	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008 001	Jun 13, 2008	Mar CAHN
>A>			@	EQ 3MG BASE	N022008 002	Jun 13, 2008	Mar CAHN
>A>	AB			EQ 4MG BASE	N022008 003	Jun 13, 2008	Mar CAHN
>A>	AB			EQ 6MG BASE	N022008 006	Apr 10, 2009	Mar CAHN
>A>	AB			EQ 8MG BASE	N022008 004	Jun 13, 2008	Mar CAHN
>A>	AB			EQ 12MG BASE	N022008 005	Oct 31, 2008	Mar CAHN
>D>	AB	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

>D>	@ SMITHKLINE BEECHAM	EQ 3MG BASE	N022008 002	Jun 13, 2008	Mar	CAHN
>D>	AB	EQ 4MG BASE	N022008 003	Jun 13, 2008	Mar	CAHN
>D>	AB	EQ 6MG BASE	N022008 006	Apr 10, 2009	Mar	CAHN
>D>	AB	EQ 8MG BASE	N022008 004	Jun 13, 2008	Mar	CAHN
>D>	AB	EQ 12MG BASE	N022008 005	Oct 31, 2008	Mar	CAHN

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

AB	SB PHARMCO	EQ 2MG BASE	N021071 002	May 25, 1999	Jan	CFTG
AB		EQ 4MG BASE	N021071 003	May 25, 1999	Jan	CFTG
AB	+	EQ 8MG BASE	N021071 004	May 25, 1999	Jan	CFTG

ROSIGLITAZONE MALEATE

AB	TEVA	EQ 2MG BASE	A076747 001	Jan 25, 2013	Jan	NEWA
AB		EQ 4MG BASE	A076747 002	Jan 25, 2013	Jan	NEWA
AB		EQ 8MG BASE	A076747 003	Jan 25, 2013	Jan	NEWA

SAQUINAVIR MESYLATE

TABLET; ORAL

INVIRASE

+	HOFFMAN LA ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004	Feb	CAHN
---	------------------	---------------	-------------	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@	DAVA PHARMS INC	5MG	A074641 001	Aug 02, 1996	Jan	DISC
---	-----------------	-----	-------------	--------------	-----	------

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149 001	Feb 25, 2013	Feb	NEWA
AB	AMNEAL PHARMS	EQ 20MG BASE	A202025 001	Feb 28, 2013	Feb	NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

>A>	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832 002	Jan 06, 2012	Mar	NEWA
>A>		22.5MG/2.5ML (9MG/ML)	N202832 003	Jan 06, 2012	Mar	NEWA
>A>		27MG/3ML (9MG/ML)	N202832 004	Jan 06, 2012	Mar	NEWA
>A>		45MG/5ML (9MG/ML)	N202832 005	Jan 06, 2012	Mar	NEWA
>A>		90MG/10ML (9MG/ML)	N202832 006	Jan 06, 2012	Mar	NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Mar	CPOT
>A>	MEDEFIL INC	9MG/ML (9MG/ML)	N202832 001	Jan 06, 2012	Mar	CPOT

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	450MG/100ML	N017864 001		Jan	DISC
---	-----------------	-------------	-------------	--	-----	------

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

>D>	+	MEDICIS	3GM/TEASPOONFUL	N020573 001	Apr 30, 1996	Mar	CFTG
>A>	AB	+	3GM/TEASPOONFUL	N020573 001	Apr 30, 1996	Mar	CFTG

		POWDER; ORAL							
>A>		SODIUM PHENYLBUTYRATE							
>A>	AB	SIGMAPHARM LABS LLC	3GM/TEASPOONFUL		A202819	001	Mar 22, 2013	Mar	NEWA
		<u>SODIUM POLYSTYRENE SULFONATE</u>							
		SUSPENSION; ORAL, RECTAL							
		SODIUM POLYSTYRENE SULFONATE							
>D>	AA	ROXANE	15GM/60ML		A089049	001	Nov 17, 1986	Mar	DISC
>A>		@	15GM/60ML		A089049	001	Nov 17, 1986	Mar	DISC
		<u>SULFACETAMIDE SODIUM</u>							
		LOTION; TOPICAL							
		KLARON							
	AB	+ VALEANT BERMUDA	10%		N019931	001	Dec 23, 1996	Feb	CAHN
		<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>							
		INJECTABLE; INJECTION							
		SULFAMETHOXAZOLE AND TRIMETHOPRIM							
>D>	+	TEVA PARENTERAL	80MG/ML;16MG/ML		A073303	001	Oct 31, 1991	Mar	CAHN
>A>	+	TEVA PHARMS USA	80MG/ML;16MG/ML		A073303	001	Oct 31, 1991	Mar	CAHN
		<u>TABLET; ORAL</u>							
>D>		SULFAMETHOPRIM							
>D>	AB	NOVEL LABS INC	400MG;80MG		A070022	001	Feb 15, 1985	Mar	DISC
>A>		@	400MG;80MG		A070022	001	Feb 15, 1985	Mar	DISC
>D>		SULFAMETHOPRIM-DS							
>D>	AB	NOVEL LABS INC	800MG;160MG		A070032	001	Feb 15, 1985	Mar	DISC
>A>		@	800MG;160MG		A070032	001	Feb 15, 1985	Mar	DISC
		<u>SUMATRIPTAN SUCCINATE</u>							
		INJECTABLE; SUBCUTANEOUS							
		SUMATRIPTAN SUCCINATE							
	AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A090641	001	Jul 28, 2010	Feb	CAHN
>D>	AP	TEVA PARENTERAL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A077907	001	Feb 06, 2009	Mar	CAHN
>A>	AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		A077907	001	Feb 06, 2009	Mar	CAHN
		<u>SYSTEM; IONTOPHORESIS</u>							
		ZECUITY							
	+	NUPATHE	EQ 6.5MG BASE/4HR		N202278	001	Jan 17, 2013	Jan	NEWA
>A>		<u>TECHNETIUM TC-99M TILMANOCEPT</u>							
>A>		INJECTABLE; INJECTION							
>A>		LYMPHOSEEK KIT							
>A>	+	NAVIDEA BIOPHARMS	N/A		N202207	001	Mar 13, 2013	Mar	NEWA
		<u>TERBUTALINE SULFATE</u>							
		INJECTABLE; INJECTION							
		TERBUTALINE SULFATE							
>D>		@ TEVA PARENTERAL	1MG/ML		A076853	001	Jul 20, 2004	Mar	CAHN
>A>		@ TEVA PHARMS USA	1MG/ML		A076853	001	Jul 20, 2004	Mar	CAHN
		<u>TESTOSTERONE</u>							
		GEL; TRANSDERMAL							
		TESTOSTERONE							
		PERRIGO ISRAEL	25MG/2.5GM PACKET		N203098	002	Jan 31, 2013	Jan	NEWA
			50MG/5GM PACKET		N203098	003	Jan 31, 2013	Jan	NEWA

GEL, METERED; TRANSDERMAL

TESTOSTERONE

PERRIGO ISRAEL

12.5MG/1.25GM ACTUATION

N203098 001 Jan 31, 2013 Jan NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

AO + ENDO PHARMS

200MG/ML

N009165 003

Jan CAHN

@

200MG/ML

N009165 001

Jan CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

>D> AB + PLIVA

450MG

A081236 001 Nov 09, 1992 Mar CAHN

>A> AB + TEVA PHARMS

450MG

A081236 001 Nov 09, 1992 Mar CAHN

THIOGUANINE

TABLET; ORAL

THIOGUANINE

>A> + ASPEN GLOBAL INC

40MG

N012429 001

Mar CAHN

>D> + GLAXOSMITHKLINE

40MG

N012429 001

Mar CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOPTIC-XE

AB + VALEANT PHARMS LLC

EQ 0.25% BASE

N020330 001 Nov 04, 1993 Jan CAHN

AB +

EQ 0.5% BASE

N020330 002 Nov 04, 1993 Jan CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

@ MYLAN PHARMS INC

EQ 2MG BASE

A076282 001 Dec 16, 2003 Feb DISC

@

EQ 4MG BASE

A076282 002 Dec 16, 2003 Feb DISC

TOBRAMYCIN

>A> POWDER; INHALATION

>A> TOBI PODHALER

>A> + NOVARTIS

28MG

N201688 001 Mar 22, 2013 Mar NEWA

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

>D> AB MYLAN

250MG

A070259 001 Jan 02, 1986 Mar CTEC

>D> AB +

500MG

A070259 003 Mar 17, 1986 Mar CTEC

>A> MYLAN PHARMS INC

250MG

A070259 001 Jan 02, 1986 Mar CTEC

>A> +

500MG

A070259 003 Mar 17, 1986 Mar CTEC

>D> AB WATSON LABS

250MG

A070514 001 Jan 09, 1986 Mar DISC

>A> @

250MG

A070514 001 Jan 09, 1986 Mar DISC

>D> AB

500MG

A070515 001 Jan 09, 1986 Mar DISC

>A> @

500MG

A070515 001 Jan 09, 1986 Mar DISC

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

AB ACTIVIS TOTOWA LLC

25MG

A078637 001 Feb 27, 2013 Feb NEWA

AB

50MG

A078637 002 Feb 27, 2013 Feb NEWA

TABLET; ORAL

TOPIRAMATE

AB	ACTIVIS TOTOWA LLC	100MG	A078637 003	Feb 27, 2013	Feb	NEWA
AB		200MG	A078637 004	Feb 27, 2013	Feb	NEWA
AB	UNICHEM LABS LTD	200MG	A090162 004	Feb 19, 2013	Feb	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB	CSPC OUYI PHARM CO	50MG	A091498 001	Mar 29, 2013	Mar	NEWA
-----	----	--------------------	------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

@ PURDUE PHARMA

@

@

		100MG	N021745 001	Dec 30, 2008	Jan	DISC
		200MG	N021745 002	Dec 30, 2008	Jan	DISC
		300MG	N021745 003	Dec 30, 2008	Jan	DISC

TRAMADOL HYDROCHLORIDE

AB1	PAR PHARM INC	100MG	A078783 001	Nov 13, 2009	Feb	CRLD
AB2 +	SUN PHARMA GLOBAL	100MG	A091607 001	Dec 30, 2011	Feb	CRLD

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVOPROST

PAR PHARM

0.004%

A091340 001	Mar 01, 2013	Feb	NEWA
-------------	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

>D>	AB	PLIVA	50MG	A071523 001	Dec 11, 1987	Mar	CAHN
>D>	AB		100MG	A071524 001	Dec 11, 1987	Mar	CAHN
>A>	AB	TEVA PHARMS USA	50MG	A071523 001	Dec 11, 1987	Mar	CAHN
>A>	AB		100MG	A071524 001	Dec 11, 1987	Mar	CAHN

URSODIOL

TABLET; ORAL

URSODIOL

AB	PAR PHARM	250MG	A202540 001	Feb 14, 2013	Feb	NEWA
AB		500MG	A202540 002	Feb 14, 2013	Feb	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

>A>	AB	ACTAVIS GRP PTC	EQ 500MG BASE	A090370 001	Mar 16, 2011	Mar	CAHN
>A>	AB		EQ 1GM BASE	A090370 002	Mar 16, 2011	Mar	CAHN
>D>	AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370 001	Mar 16, 2011	Mar	CAHN
>D>	AB		EQ 1GM BASE	A090370 002	Mar 16, 2011	Mar	CAHN

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB	SUN PHARM INDS LTD	250MG	A091037 001	Feb 22, 2013	Feb	NEWA
----	--------------------	-------	-------------	--------------	-----	------

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

>D>	AP	INTL MEDICATION	2.5MG/ML	A070451 001	Dec 16, 1985	Mar	DISC
>A>		@	2.5MG/ML	A070451 001	Dec 16, 1985	Mar	DISC

VERTEPORFIN

INJECTABLE; INJECTION
VISUDYNE

+ VALEANT PHARMS INC 15MG/VIAL N021119 001 Apr 12, 2000 Jan CAHN

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	AMNEAL PHARMS	1MG	A202202 001	Mar 04, 2013	Feb	NEWA
AB		2MG	A202202 002	Mar 04, 2013	Feb	NEWA
AB		2.5MG	A202202 003	Mar 04, 2013	Feb	NEWA
AB		3MG	A202202 004	Mar 04, 2013	Feb	NEWA
AB		4MG	A202202 005	Mar 04, 2013	Feb	NEWA
AB		5MG	A202202 006	Mar 04, 2013	Feb	NEWA
AB		6MG	A202202 007	Mar 04, 2013	Feb	NEWA
AB		7.5MG	A202202 008	Mar 04, 2013	Feb	NEWA
AB		10MG	A202202 009	Mar 04, 2013	Feb	NEWA

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

AB	HEC PHARM USA INC	300MG	A202058 001	Oct 07, 2011	Feb	CMFD
	@	300MG	A202058 001	Oct 07, 2011	Jan	DISC

ZOLEDRONIC ACID

INJECTABLE; INJECTION

ZOLEDRONIC ACID

>A>	AP	DR REDDYS LABS LTD	EQ 5MG BASE/100ML	A091363 001	Mar 29, 2013	Mar	NEWA
>A>	AP	EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801 001	Mar 29, 2013	Mar	NEWA

INJECTABLE; IV (INFUSION)

RECLAST

>D>	+	NOVARTIS	EQ 5MG BASE/100ML	N021817 001	Apr 16, 2007	Mar	CTEC
>A>	AP	+	EQ 5MG BASE/100ML	N021817 001	Apr 16, 2007	Mar	CTEC

ZOLEDRONIC ACID

	AP	ACTAVIS INC	EQ 4MG BASE/5ML	A202472 001	Mar 04, 2013	Feb	NEWA
	AP	AGILA SPECLTS	EQ 4MG BASE/5ML	A202650 001	Mar 04, 2013	Feb	NEWA
	AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186 001	Mar 04, 2013	Feb	NEWA
>A>	AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783 001	Mar 12, 2013	Mar	NEWA
>A>	AP	HOSPIRA INC	EQ 5MG BASE/100ML	A202837 001	Apr 05, 2013	Mar	NEWA
	AP	PHARMACEUTICS	EQ 4MG BASE/5ML	A091170 001	Mar 04, 2013	Feb	NEWA
	+	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018 001	Mar 04, 2013	Feb	NEWA
	AP		EQ 4MG BASE/5ML	A202746 001	Mar 04, 2013	Feb	NEWA

ZOMETA

AP	+	NOVARTIS	EQ 4MG BASE/5ML	N021223 002	Mar 07, 2003	Feb	CFTG
----	---	----------	-----------------	-------------	--------------	-----	------

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

>A>	AB	WATSON LABS INC FL	6.25MG	A090153 001	Mar 25, 2013	Mar	NEWA
>A>	AB		12.5MG	A090153 002	Mar 25, 2013	Mar	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

	@	COREPHARMA	25MG	A077876 001	Feb 21, 2007	Feb	DISC
--	---	------------	------	-------------	--------------	-----	------

CAPSULE; ORAL

ZONISAMIDE

	@ COREPHARMA	50MG	A077876 002	Feb 21, 2007	Feb	DISC
	@	100MG	A077876 003	Feb 21, 2007	Feb	DISC
>D>	AB	DR REDDYS LABS LTD	25MG	A077645 002	Sep 29, 2006	Mar DISC
>A>	@	25MG	A077645 002	Sep 29, 2006	Mar	DISC
>D>	AB	50MG	A077645 003	Sep 29, 2006	Mar	DISC
>A>	@	50MG	A077645 003	Sep 29, 2006	Mar	DISC
>D>	AB	100MG	A077645 001	Dec 22, 2005	Mar	DISC
>A>	@	100MG	A077645 001	Dec 22, 2005	Mar	DISC

OTC DRUG PRODUCT LIST - 33RD EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

2-1

ASPIRIN

CAPSULE; ORAL

ASPIRIN

+	PLX PHARMA	325MG	N203697 001	Jan 14, 2013	Jan	NEWA
---	------------	-------	-------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

CHILDREN'S ZYRTEC ALLERGY

+	MCNEIL CONS	5MG	N021621 003	Nov 16, 2007	Feb	CRLD
---	-------------	-----	-------------	--------------	-----	------

@		10MG	N021621 004	Nov 16, 2007	Feb	DISC
---	--	------	-------------	--------------	-----	------

CHILDREN'S ZYRTEC HIVES RELIEF

+	MCNEIL CONS	5MG	N021621 005	Nov 16, 2007	Feb	CRLD
---	-------------	-----	-------------	--------------	-----	------

@		10MG	N021621 006	Nov 16, 2007	Feb	DISC
---	--	------	-------------	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

>D>	CHLORASCRUB MAXI SWABSTICK		N021524 003	Jun 03, 2005	Mar	CTNA
-----	----------------------------	--	-------------	--------------	-----	------

>D>	+	PROF DSPLS	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005	Mar	CTNA
-----	---	------------	-------------------	-------------	--------------	-----	------

>D>	CHLORASCRUB SWAB		N021524 001	Jun 03, 2005	Mar	CTNA
-----	------------------	--	-------------	--------------	-----	------

>D>	+	PROF DSPLS	3.15%;70% (1ML)	N021524 001	Jun 03, 2005	Mar	CTNA
-----	---	------------	-----------------	-------------	--------------	-----	------

>D>	CHLORASCRUB SWABSTICK		N021524 002	Jun 03, 2005	Mar	CTNA
-----	-----------------------	--	-------------	--------------	-----	------

>D>	+	PROF DSPLS	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005	Mar	CTNA
-----	---	------------	-------------------	-------------	--------------	-----	------

>A>	PREVANTICS MAXI SWABSTICK		N021524 003	Jun 03, 2005	Mar	CTNA
-----	---------------------------	--	-------------	--------------	-----	------

>A>	+	PROF DSPLS	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005	Mar	CTNA
-----	---	------------	-------------------	-------------	--------------	-----	------

>A>	PREVANTICS SWAB		N021524 001	Jun 03, 2005	Mar	CTNA
-----	-----------------	--	-------------	--------------	-----	------

>A>	+	PROF DSPLS	3.15%;70% (1ML)	N021524 001	Jun 03, 2005	Mar	CTNA
-----	---	------------	-----------------	-------------	--------------	-----	------

>A>	PREVANTICS SWABSTICK		N021524 002	Jun 03, 2005	Mar	CTNA
-----	----------------------	--	-------------	--------------	-----	------

>A>	+	PROF DSPLS	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005	Mar	CTNA
-----	---	------------	-------------------	-------------	--------------	-----	------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

	AVANTHI INC	6MG;120MG	A078648 001	Feb 27, 2013	Feb	NEWA
--	-------------	-----------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	30MG	A202978 001	Jan 18, 2013	Jan	NEWA
--	--------------------	------	-------------	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A202978 002	Jan 18, 2013	Jan	NEWA
--	--------------------	------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

	LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013	Jan	NEWA
--	-----------	--------	-------------	--------------	-----	------

AB	NOVEL LABS INC	1.5MG	A202508 001	Feb 22, 2013	Feb	NEWA
----	----------------	-------	-------------	--------------	-----	------

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

@	WATSON LABS INC FL	5MG;120MG	A076208 001	Jan 28, 2004	Feb	DISC
---	--------------------	-----------	-------------	--------------	-----	------

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE NITRATE

APHENA PHARMA MD 2%

A074366 001 Feb 22, 1996 Jan CAHN

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC 0.025%;0.3%

A202795 001 Jan 24, 2013 Jan NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL FOR WOMEN

+ MSD CONSUMER 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PAR PHARM 17GM/SC00PFUL

A079214 001 Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>D> WATSON LABS EQ 75MG BASE

A075212 001 Jan 14, 2000 Mar DISC

>A> @ EQ 75MG BASE

A075212 001 Jan 14, 2000 Mar DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2013

NO MARCH 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2013 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 33RD EDITION

A - 1

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	>A> 8399445	Aug 24, 2025	U-1373			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001					NPP	Feb 01, 2016
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N203414 001	5965584	Jun 19, 2016	U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N203414 002	5965584	Jun 19, 2016	U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 001	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 002	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 003	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 004	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 005	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N022426 006	5965584	Jun 19, 2016	DP U-1339		NCE	Jan 25, 2018
	6150383	Jun 19, 2016	U-1330		NC	Jan 25, 2016
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>AMOXICILLIN - MOXATAG</u>						
N050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1200			
<u>APIXABAN - ELIQUIS</u>						
N202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1200			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N202971 001					NDF	Feb 28, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N202971 002					NDF	Feb 28, 2016
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	>A> 8354409	Apr 19, 2022	DP U-1371			
<u>BUDESONIDE - UCERIS</u>						
N203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	>A> 8387615	Nov 10, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	>A> 8387615	Nov 10, 2024	DP			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 001					ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 002					ODE	Nov 29, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N204042 001					>A> NCE	Mar 29, 2018
<u>CANAGLIFLOZIN - INVOKANA</u>						
N204042 002					>A> NCE	Mar 29, 2018
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A090704 003					>A> PC	Jun 02, 2013
<u>CELECOXIB - CELEBREX</u>						
N200998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N200998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1352			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1348			
	RE44048*PED	Dec 02, 2015				
<u>CICLESONIDE - ALVESCO</u>						
N021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N022004 001	8371292	Aug 25, 2027	U-1356			
	>A> 8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N02129 001	8371292	Aug 25, 2027	U-1357			
<u>CLOBAZAM - ONFI</u>						
N203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A201402 001					PC	Jul 31, 2013
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100 001	>A> 7635704	Oct 26, 2026	DS DP U-257			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004					D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005					D-135 PED	Feb 01, 2016 Aug 01, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976	006				D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895	001				D-135 PED	Feb 01, 2016 Aug 01, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882	001				I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882	002				I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N021882	003				I-665	Jan 23, 2016
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992	001	>A> 6673838	Feb 11, 2022	DS DP U-860		
		>A> 6673838	Feb 11, 2022	DS DP U-1364		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992	002	>A> 6673838	Feb 11, 2022	DS DP U-860		
		>A> 6673838	Feb 11, 2022	DS DP U-1364		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N021038	001	>A> 4910214	Jul 15, 2013	DS DP U-421		
		>A> 4910214*PED	Jan 15, 2014			
		>A> 6716867	Mar 31, 2019	U-572		
		>A> 6716867*PED	Oct 01, 2019			
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212	001	>A> 6114319	May 18, 2019	DP	>A> I-653	Jun 13, 2015
		>A> 6114319*PED	Nov 18, 2019		>A> M-127	Mar 22, 2016
					>A> ODE	Jun 13, 2019
					>A> PED	Dec 13, 2019
					>A> PED	Sep 22, 2016
					>A> PED	Dec 13, 2015
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N204063	001				>A> NCE	Mar 27, 2018
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N204063	002				>A> NCE	Mar 27, 2018
<u>DOXYCYCLINE - ORACEA</u>						
N050805	001	>A> 8394406	Dec 24, 2025	DP U-925		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N021676	001	RE43916	Jun 30, 2014	U-1326		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N022532	001	RE43916	Jun 30, 2014	U-1326		
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427	001				M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427	002				M-61 PED	Oct 18, 2015 Apr 18, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427	004				M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>EFAVIRENZ - SUSTIVA</u>						
N020972	001	5519021	May 21, 2013	DS DP		
		5519021*PED	Nov 21, 2013			
		5663169	Sep 02, 2014		U-257	
		5663169*PED	Mar 02, 2015			
		6238695	Apr 06, 2019	DP		
		6238695*PED	Oct 06, 2019			
		6555133	Apr 06, 2019		U-248	
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972	002	5519021	May 21, 2013	DS DP		
		5519021*PED	Nov 21, 2013			
		5663169	Sep 02, 2014		U-257	
		5663169*PED	Mar 02, 2015			
		6238695	Apr 06, 2019	DP		
		6238695*PED	Oct 06, 2019			
		6555133	Apr 06, 2019		U-248	
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N020972	003	5519021	May 21, 2013	DS DP		
		5519021*PED	Nov 21, 2013			
		5663169	Sep 02, 2014		U-257	
		5663169*PED	Mar 02, 2015			
		6238695	Apr 06, 2019	DP		
		6238695*PED	Oct 06, 2019			
		6555133	Apr 06, 2019		U-248	
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 001	5519021	May 21, 2013				
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N021360 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014			U-248	
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014			U-750	
	5663169	Sep 02, 2014			U-1170	
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	>A> 8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	>A> 8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 001	8318802	Mar 15, 2027	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N022260 002	8318802	Mar 15, 2027	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 001	>A> 5646286	Aug 12, 2014	DS DP			
	>A> 6024976	Jan 07, 2014	DS DP			
	>A> 8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 002	>A> 5646286	Aug 12, 2014	DS DP			
	>A> 6024976	Jan 07, 2014	DS DP			
	>A> 8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 003	>A> 5646286	Aug 12, 2014	DS DP			
	>A> 6024976	Jan 07, 2014	DS DP			
	>A> 8231906	May 24, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 004	>A> 5646286	Aug 12, 2014	DS DP			
	>A> 6024976	Jan 07, 2014	DS DP			
	>A> 8231906	May 24, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N204061 001					>A> NP	Mar 28, 2016
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	>A> 8410131	May 22, 2025	DS DP U-1368			
	>A> 8410131*PED	Nov 22, 2025				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	>A> 8410131	May 22, 2025	DS DP U-1368			
	>A> 8410131*PED	Nov 22, 2025				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	>A> 8410131	May 22, 2025	DS DP U-1368			
	>A> 8410131*PED	Nov 22, 2025				
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	>A> 8410131	May 22, 2025	DS DP U-1368			
	>A> 8410131*PED	Nov 22, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	>A> 5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	>A> 5665772	Sep 09, 2019	DS DP U-1049			
	>A> 5665772*PED	Mar 09, 2020				
	>A> 6004973	Jul 12, 2016	DP U-1365			
	>A> 6004973	Jul 12, 2016	DP U-1049			
	>A> 6004973*PED	Jan 12, 2017				
	>A> 6440990	Sep 24, 2013	DP U-1365			
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6440990*PED	Mar 24, 2014				
	>A> 6455518	Jul 29, 2017	U-1365			
	>A> 6455518	Jul 29, 2017	U-1049			
	>A> 6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	>A> 5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	>A> 5665772	Sep 09, 2019	DS DP U-1049			
	>A> 5665772*PED	Mar 09, 2020				
	>A> 6004973	Jul 12, 2016	DP U-1365			
	>A> 6004973	Jul 12, 2016	DP U-1049			
	>A> 6004973*PED	Jan 12, 2017				
	>A> 6440990	Sep 24, 2013	DP U-1365			
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6440990*PED	Mar 24, 2014				
	>A> 6455518	Jul 29, 2017	U-1365			
	>A> 6455518	Jul 29, 2017	U-1049			
	>A> 6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	>A> 5665772	Sep 09, 2019	DS DP U-1365		I-668	Feb 15, 2016
	>A> 5665772	Sep 09, 2019	DS DP U-1049			
	>A> 5665772*PED	Mar 09, 2020				
	>A> 6004973	Jul 12, 2016	DP U-1365			
	>A> 6004973	Jul 12, 2016	DP U-1049			
	>A> 6004973*PED	Jan 12, 2017				
	>A> 6440990	Sep 24, 2013	DP U-1365			
	>A> 6440990	Sep 24, 2013	DP U-1049			
	>A> 6440990*PED	Mar 24, 2014				
	>A> 6455518	Jul 29, 2017	U-1365			
	>A> 6455518	Jul 29, 2017	U-1049			
	>A> 6455518*PED	Jan 29, 2018				
<u>FEBUXOSTAT - ULORIC</u>						
N021856 001	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N021856 002	8372872	Sep 08, 2031	U-1346			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	8338478	May 11, 2019	DS DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	8338478	May 11, 2019	DS DP U-913			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8347879	Apr 01, 2027	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 001	>A> 5929028	Jan 14, 2018	DP U-567			
	>A> 5929028	Jan 14, 2018	DP U-1366			
	>A> 7563763	Aug 23, 2019	U-993			
	>A> 7563763	Aug 23, 2019	U-1367			
	>A> 7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 002	>A> 5929028	Jan 14, 2018	DP U-567			
	>A> 5929028	Jan 14, 2018	DP U-1366			
	>A> 7563763	Aug 23, 2019	U-993			
	>A> 7563763	Aug 23, 2019	U-1367			
	>A> 7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 003	>A> 5929028	Jan 14, 2018	DP U-567			
	>A> 5929028	Jan 14, 2018	DP U-1366			
	>A> 7563763	Aug 23, 2019	U-993			
	>A> 7563763	Aug 23, 2019	U-1367			
	>A> 7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021211 004	>A> 5929028	Jan 14, 2018	DP U-567			
	>A> 5929028	Jan 14, 2018	DP U-1366			
	>A> 7563763	Aug 23, 2019	U-993			
	>A> 7563763	Aug 23, 2019	U-1367			
	>A> 7563763	Aug 23, 2019	U-1183			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 001	>A> 5767251	Jun 16, 2015	DS			
	>A> 5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N021273 002	>A> 5767251	Jun 16, 2015	DS			
	>A> 5929028	Jan 14, 2018	DP U-1366			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8333992	Oct 25, 2022	DP U-1114			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 001					>A> NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 002					>A> NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 003					>A> NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N204781 004					>A> NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 002					NCE	Jul 03, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION</u>						
N021057 001	6653286	Jun 16, 2018	U-1354			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N020622 002	>A> 8367605	May 24, 2014	DS			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N203284 001					NE	Feb 01, 2016
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	>A> 8399446	Feb 09, 2030	U-1287			
	>A> 8415335	Feb 09, 2030	U-1287			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	RE43932	Jan 16, 2019	DS DP		>A> ODE	Jan 25, 2020
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	RE43932	Jan 16, 2019	DS DP		>A> ODE	Jan 25, 2020
	RE43932*PED	Jul 16, 2019				
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N022290 001					>A> I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N021135 005					>A> NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	8367102	Sep 21, 2021	U-1347			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	>A> 8377982	May 28, 2024	U-1363			
	>A> 8377982*PED	Nov 28, 2024				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	>A> 8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	>A> 8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	>A> 8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	>A> 8404717	Apr 11, 2023	U-1215			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	>A> 8404717	Apr 11, 2023	U-1215			
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 001					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVONORGESTREL - SKYLA</u>						
N203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 001	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 002	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N203858 003	5712279	Feb 21, 2015	DS	U-1317	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	>A> 8377952	Oct 22, 2027		U-1372		
	>A> 8377952*PED	Apr 22, 2028				
	>A> 8399015	Aug 25, 2024	DP			
	>A> 8399015*PED	Feb 25, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	>A> 8377952	Oct 22, 2027			U-1372	
	>A> 8377952*PED	Apr 22, 2028				
	>A> 8399015	Aug 25, 2024	DP			
	>A> 8399015*PED	Feb 25, 2025				
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N022549 001	>A> 6716416	May 20, 2022	DP			
	>A> 7052679	Mar 20, 2022	DP			
	>A> 7078020	Oct 26, 2021	DP		U-1375	
	>A> 7090830	Oct 26, 2021	DP			
	>A> 7458374	Aug 18, 2024	DP			
	>A> 7537009	Oct 26, 2021	DP			
	>A> 7585493	Oct 26, 2021	DP			
	>A> 7601337	Oct 26, 2021	DP			
	>A> 8074644	Oct 26, 2021	DP			
	>A> 8173107	Oct 26, 2021	DP			
	>A> 8235037	Oct 26, 2021	DP			
	>A> 8387612	Oct 23, 2026	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8389542	Nov 14, 2022	DP		U-1345	
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N203595 001					NC	Jan 18, 2016
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N202100 001	>A> 8062667	Mar 29, 2029	DP			
	>A> 8287903	Feb 15, 2031	DP			
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021			U-1353	
	7511131	Dec 13, 2025	DS			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050703 001	5569672	Oct 29, 2013			U-1358	
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	5569672	Oct 29, 2013			U-1358	
<u>NEPAFENAC - NEPAFENAC</u>						
N203491 001	5475034	Jun 06, 2014			U-100	
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	>A> 8389537	Jul 18, 2026	DS DP U-1374			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	>A> 8389537	Jul 18, 2026	DS DP U-1374			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861 001	>A> 8399508	Sep 17, 2022	U-726			
	>A> 8399508*PED	Mar 17, 2023				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 002					NPP	Dec 21, 2015
<u>OSPEMIFENE - OSPHENA</u>						
N203505 001	>A> 6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	>A> 8236861	Feb 13, 2024	U-1370			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 005					>A> M-93	Jul 29, 2019
					>A> NCE	Apr 30, 2014
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	RE42152	Dec 10, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N204026 001	>A> 5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	>A> 6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	>A> 6315720	Oct 23, 2020	U-1361			
	>A> 6316471	Aug 10, 2016	DP U-1360			
	>A> 6476052	Jul 24, 2016	DP U-1360			
	>A> 6561976	Aug 28, 2018	U-1361			
	>A> 6561977	Oct 23, 2020	U-1361			
	>A> 6755784	Oct 23, 2020	U-1361			
	>A> 6908432	Aug 28, 2018	U-1361			
	>A> 8158653	Aug 10, 2016	DP			
	>A> 8198262	Oct 19, 2024	U-1360			
	>A> 8204763	Aug 28, 2018	U-1361			
	>A> 8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N204026 002	>A> 5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	>A> 6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	>A> 6315720	Oct 23, 2020	U-1361			
	>A> 6316471	Aug 10, 2016	DP U-1360			
	>A> 6476052	Jul 24, 2016	DP U-1360			
	>A> 6561976	Aug 28, 2018	U-1361			
	>A> 6561977	Oct 23, 2020	U-1361			
	>A> 6755784	Oct 23, 2020	U-1361			
	>A> 6908432	Aug 28, 2018	U-1361			
	>A> 8158653	Aug 10, 2016	DP			
	>A> 8198262	Oct 19, 2024	U-1360			
	>A> 8204763	Aug 28, 2018	U-1361			
	>A> 8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N204026 003	>A> 5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	>A> 6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	>A> 6315720	Oct 23, 2020	U-1361			
	>A> 6316471	Aug 10, 2016	DP U-1360			
	>A> 6476052	Jul 24, 2016	DP U-1360			
	>A> 6561976	Aug 28, 2018	U-1361			
	>A> 6561977	Oct 23, 2020	U-1361			
	>A> 6755784	Oct 23, 2020	U-1361			
	>A> 6908432	Aug 28, 2018	U-1361			
	>A> 8158653	Aug 10, 2016	DP			
	>A> 8198262	Oct 19, 2024	U-1360			
	>A> 8204763	Aug 28, 2018	U-1361			
	>A> 8315886	Oct 23, 2020	U-1361			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N204026 004	>A> 5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	>A> 6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	>A> 6315720	Oct 23, 2020	U-1361			
	>A> 6316471	Aug 10, 2016	DP U-1360			
	>A> 6476052	Jul 24, 2016	DP U-1360			
	>A> 6561976	Aug 28, 2018	U-1361			
	>A> 6561977	Oct 23, 2020	U-1361			
	>A> 6755784	Oct 23, 2020	U-1361			
	>A> 6908432	Aug 28, 2018	U-1361			
	>A> 8158653	Aug 10, 2016	DP			
	>A> 8198262	Oct 19, 2024	U-1360			
	>A> 8204763	Aug 28, 2018	U-1361			
	>A> 8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N203469 002					ODE	Dec 14, 2019
<u>PRALATREXATE - FOLOTYN</u>						
N022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N022468 002	6028071	Jul 16, 2022	DS DP U-1004			
<u>PREDNISONE - RAYOS</u>						
N202020 001	>A> 8394407	Apr 23, 2024	DP U-1362			
<u>PREDNISONE - RAYOS</u>						
N202020 002	>A> 8394407	Apr 23, 2024	DP U-1362			
<u>PREDNISONE - RAYOS</u>						
N202020 003	>A> 8394407	Apr 23, 2024	DP U-1362			
<u>PREGABALIN - LYRICA</u>						
N022488 001					I-651	Jun 20, 2015
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N204736 001					>A> NDF >A> PED	Mar 26, 2016 Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N204736 002					>A> NDF >A> PED	Mar 26, 2016 Sep 26, 2016
<u>REGORAFENIB - STIVARGA</u>						
N203085 001					I-667 >A> ODE	Feb 25, 2016 Feb 25, 2020
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A078173 001					>A> PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A078173 002					>A> PC	Jun 29, 2013
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 001	>A> 5670524	Sep 23, 2014	DS DP U-833			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 003	>A> 5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 004	>A> 5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N020533 005	>A> 5670524	Sep 23, 2014	DS DP U-833			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N020628 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N021785 001					M-61 PED	Nov 30, 2015 May 30, 2016
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP		Y	
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP		Y	
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP		Y	
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP		Y	
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP		Y	
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N022207 001					>A> NCE	Mar 13, 2018
<u>TEDUGLUTIDE - GATTEX KIT</u>						
N203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELIVUDINE - TYZEKA</u>						
N022011 001					M-124	Jan 28, 2016
<u>TELIVUDINE - TYZEKA</u>						
N022154 001					M-124	Jan 28, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098 001					NP	Jan 31, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098	002				NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N203098	003				NP	Jan 31, 2016
<u>TIGECYCLINE - TYGACIL</u>						
N021821	001	8372995	Oct 08, 2030	DP		
<u>TOBRAMYCIN - BETHKIS</u>						
N201820	001	6987094	Sep 22, 2022	DP		
		7696178	Mar 17, 2023	DP		
		7939502	Jun 14, 2022	U-1324		
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N201688	001				>A> NP	Mar 22, 2016
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A202093	001				>A> PC	Jul 02, 2013
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994	001	8388941	Sep 20, 2027	DP		
<u>TROSPIUM CHLORIDE - TROSPIUM CHLORIDE</u>						
A091289	001				PC	Apr 10, 2013
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N021214	001	6770675	Nov 24, 2018	DP	U-1322	
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817	001	>A> 8052987	Oct 27, 2023	U-1199		

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>